**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 5842**

**Columns:** REVIEW

**Liquid biopsy of gastric cancer patients: Circulating tumor cells and cell-free nucleic acids**

Tsujiura M *et al*. Liquid biopsy of gastric cancer patients

Masahiro Tsujiura, Daisuke Ichikawa, Hirotaka Konishi, Shuhei Komatsu, Atsushi Shiozaki, Eigo Otsuji

**Masahiro Tsujiura, Daisuke Ichikawa, Hirotaka Konishi, Shuhei Komatsu, Atsushi Shiozaki, Eigo Otsuji,** Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan

**Author contributions:** Tsujiura M and Ichikawa D equally contributed to this paper; Konishi H, Shuhei K and Shiozaki A assisted collection and assembly of data; Otsuji E supervised the work.

**Correspondence to: Daisuke Ichikawa, MD, PhD,** Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan. ichikawa@koto.kpu-m.ac.jp

**Telephone:** +81-75-2515527 **Fax:** +81-75-2515522

**Received:** September 26, 2013  **Revised:** December 27, 2013

**Accepted:** February 20, 2014

**Published online:**

**Abstract**

To improve the clinical outcomes of cancer patients, early detection and accurate monitoring of diseases are necessary. Numerous genetic and epigenetic alterations contribute to oncogenesis and cancer progression, and analyses of these changes have been increasingly utilized for diagnostic, prognostic and therapeutic purposes in malignant diseases including gastric cancer (GC). Surgical and/or biopsy specimens are generally used to understand the tumor-associated alterations; however, those approaches cannot always be performed because of their invasive characteristics and may fail to reflect current tumor dynamics and drug sensitivities, which may change during the therapeutic process. Therefore, the importance of developing a non-invasive biomarker with the ability to monitor real-time tumor dynamics should be emphasized. This concept, so called “liquid biopsy”, would provide an ideal therapeutic strategy for an individual cancer patient and would facilitate the development of “tailor-made” cancer management programs. In the blood of cancer patients, the presence and potent utilities of circulating tumor cells (CTCs) and cell-free nucleic acids (cfNAs) such as DNA, mRNA and microRNA have been recognized, and their clinical relevance is attracting considerable attention. In this review, we discuss recent developments in this research field as well as the relevance and future perspectives of CTCs and cfNAs in cancer patients, especially focusing on GC.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Gastric cancer; Biomarker; Liquid biopsy; Circulating tumor cells; Cell-free nucleic acids; MicroRNA

**Core tip:** The potent utilities of circulating tumor cells and cell-free nucleic acids have recently attracted attention toward their clinical application in therapeutic management of cancer patients. The concept of “liquid biopsy” can allow for repeated samplings and real-time monitoring of tumor dynamics in each individual patient and consequently would facilitate the development of “tailor-made” cancer management programs. Before translating this novel diagnostic and prognostic assay into the clinical settings, further large-scale studies with well-established methods are required to validate its clinical relevance.

Tsujiura M, Ichikawa D, Konishi H, Komatsu S, Shiozaki A, Otsuji E. Liquid biopsy of gastric cancer patients: Circulating tumor cells and cell-free nucleic acids. *World J Gastroenterol* 2014;

**Available from:** URL: http://www.wjgnet.com/esps/

**DOI:** <http://dx.doi.org/10.3748/wjg.v20.i0.0000>

**INTRODUCTION**

Gastric cancer (GC) is the fourth most common cancer and the second leading cause of cancer-related death in the world[[1](#_ENREF_1)]. Although recent improvements in diagnostic techniques and peri-operative management have resulted in an increase in the early detection of GC and a decrease in its mortality in the past decades, a total of 986600 new GC cases and 738000 deaths are estimated to have occurred in 2008 worldwide[[1](#_ENREF_1)]. Several factors seem to restrict diagnostic and therapeutic strategy for treatment of GC and, consequently, to incur the insufficient survival rate: (1) a lack of satisfactory diagnostic assays for early detection of GC; (2) an absence of valuable prognostic indicators; (3) the insufficient effectiveness of current treatments including surgery and chemotherapy for GC patients with advanced stages; and (4) poorly understood mechanisms of tumor progression and resistance to treatments, and a consequent deficiency of targeted therapy. Therefore, the importance of developing useful diagnostic and monitoring tools should be emphasized to improve the clinical outcome of patients with GC.

In the past few decades, numerous studies have demonstrated the potential utility of blood-based biomarkers such as circulating tumor cells (CTCs) and cell-free nucleic acids (cfNAs)[[2-5](#_ENREF_2)]. These promising markers are considered to possess great potential and could facilitate therapeutic strategies for cancer including the following: early detection of diseases, predication of prognostic outcome, monitoring of tumor dynamics and development of novel targeted treatments.

Generally, tumor-linked genetic alterations are investigated using tissue samples from surgical or biopsy specimens. These procedures cannot be conducted routinely owing to their invasive nature especially in recurrent and/or metastatic cases with anatomical and/or clinical difficulties. Moreover, a result acquired from a single biopsy can provide only spatiotemporally restricted information and may fail to reflect its heterogeneity and inconsistent tumor characteristics. Detecting CTCs and cfNAs could serve as a “liquid biopsy” for cancer patients, which would be less invasive compared to surgical or endoscopic biopsy and allow us to have repeated samplings and to track the current status of tumor characteristics, such as therapeutic efficiency and resistance. From these viewpoints, the concept of “liquid biopsy” may lead to a better understanding of the genetic landscape in both primary and metastatic lesions as well as the opportunity for tracing genomic evolution.

In this article, we review the historical backgrounds, characterizations and recent developments of both CTCs and cfNAs in cancer research including GC and discuss future perspectives.

**BIOLOGY AND DETECTION OF CTCs**

In 1869, Ashworth reported the presence of CTCs for the first time in a case of a metastatic cancer patient, in whom cells similar to those in the primary tumors were found in the blood at autopsy[[6](#_ENREF_6)]. Since then, various studies have demonstrated the identification and characterization of CTCs in peripheral blood of patients with various malignancies, validating Ashworth’s previous remarks. Generally, CTCs are considered to appear at very low concentrations in the peripheral blood of cancer patients, usually a single tumor cell in a background of millions of blood cells[[7](#_ENREF_7),[8](#_ENREF_8)]. Thus, the accurate detection of CTCs with sufficient sensitivity and specificity has been a major technical challenge for researchers (Figure 1).

***Techniques for the isolation and enrichment of CTCs***

The approaches of CTC isolation/enrichment can be mainly categorized into two groups: (1) physical methods; and (2) biological methods. Isolation based on physical properties does not require the immunological labeling of CTCs because it depends on the characteristics of CTCs, such as size, density, electric charge, migratory capacity and deformability. These methods include density gradient centrifugation, filtration, and dielectrophoresis. Several filtration-based approaches have been developed based on the concept that the majority of CTCs derived from epithelial cancers are generally larger in diameter than other blood cells[[9](#_ENREF_9),[10](#_ENREF_10)]. However, significant variations in cell size within an individual patient as well as in different types of tumor cells have been reported[[11-13](#_ENREF_11)]. Therefore, new approaches using multiple filters have been investigated to resolve those issues and achieve the accurate enrichment of CTCs[[14](#_ENREF_14),[15](#_ENREF_15)]. While those new approaches are likely to possess great promise in isolating CTCs, further validation studies should be conducted to verify their significance.

 Biological methods are another popular approach for the isolation of CTCs, which rely on immunological antibody-based capture of CTCs. In general, this assay involves positive selection with antibodies against tumor-associated antigens, such as epithelial cell adhesion (EpCAM) and cytokeratins (CKs), as well as negative selection with antibodies against the common leukocyte antigen CD45. In particular, EpCAM has been demonstrated to be over expressed and to function as an oncogene in human epithelial cancers including GC[[16-18](#_ENREF_16)]. Among several technologies based on antibody-based isolation, the CellSearch system (Veridex) is the most widely used separation system. In this platform, immunomagnetic beads coated with anti-EpCAM antibodies capture CTCs, followed by immunostaining with both positive markers, which are CK8/18/19 for cytoplasmic epithelial markers and DAPI for nucleic acids, and a negative marker, leukocyte-specific marker CD45. Accumulating studies have demonstrated the usefulness of the CellSearch system as diagnostic and prognostic indicator in patients with metastatic disease. To date, it is the only technology that has been approved by the US Food and Drug Administration for the detection of CTCs in the peripheral blood of patients with metastatic breast, prostate and colon cancers[[19-24](#_ENREF_19)].

CTCs are generally thought to be quite heterogeneous in both phenotype and genotype, and only a few cells with malignant features could develop into metastatic tumors. During the journey toward the development of a metastatic lesion, some CTCs might undergo the epithelial-to-mesenchymal transition (EMT), which is characterized by decreased expression of epithelial markers and the acquisition of mesenchymal features[[25](#_ENREF_25)]. The EMT has been proposed to be frequently related with cancer aggressiveness and might increase the ability of tumor cells to migrate. Although the identification of EMT-like cancer cells in the bloodstream and its relevance to cancer dissemination is currently under evaluation, assays targeting only epithelial cells may miss the most invasive and potentially significant subpopulation with respect to cancer progression. Therefore, alternative enrichment approaches with different epithelial antigens or negative selection methods aimed to avoid the biased selection of CTC population might be advantageous.

Tumor-specific markers, such as human epidermal growth factor 2 (HER2), prostate-specific antigen (PSA), mucin-1/2 (MUC1/2) and carcinoembryonic antigen (CEA), have also been implemented to capture CTCs more specifically and adapt to the heterogeneity of CTCs in immunological approaches. More recently, a microfluidic-based device, called the “CTC-Chip”, has been developed for CTC cell detection strategies with a significant increase in yield and purity. Using this new technology, in which whole blood is flowing through chips with automatically optimized flow kinetics, microposts coated with anti-EpCAM antibodies capture CTCs directly from small volumes of blood samples. The CTCs are then stained with secondary antibodies against either CKs or tissue-specific markers, such as PSA in prostate cancer or HER2 in breast cancer, followed by automated scanning of the microposts. Several studies have demonstrated the potent usefulness of this method due to its enhanced sensitivity and specificity, in that the higher number of isolated CTCs facilitates dynamic monitoring during a time course of cancer therapies[[26-28](#_ENREF_26)]. Moreover, recent technological progress has allowed for the isolation and analysis of single intact CTCs[[29-31](#_ENREF_29)]. These remarkable approaches should have major impacts and further understanding of the biology and significance of those heterogeneous populations.

Although most of these technologies have used blood samples *in vitro*, a new revolutionary *in vivo* approach allows the enrichment of CTCs directly from a peripheral vein of patients[[32](#_ENREF_32)] (Figure 1). In this system, a structured medical Seldinger guidewire is functionalized with the attachment of EpCAM antibodies. The device is inserted into a peripheral vein, which enables the capture of a large number of CTCs from up to 1.5 L of blood over the duration of 30 min. Despite its potent utility, a large-scale study is required to verify its relevance and to eliminate the possibility of adverse effects.

***Techniques for the detection and identification of CTCs***

After enrichment of CTCs, identification procedures are conducted to investigate their genetic and biological profiles in detail. Various methodologies for this process have been advocated and developed in the past few decades, ranging from cytometric/ protein-based approaches to polymerase chain reaction (PCR)-based approaches. The former approaches involve conventional methods, such as immunostaining for specific markers, fluorescence *in situ* hybridization (FISH) and comparative genomic hybridization, and newly developed methods, such as fiber-optic array scanning technology with high throughput in CTC screening[[33](#_ENREF_33),[34](#_ENREF_34)] and epithelial immunospot, which can detect proteins secreted from CTCs[[35-37](#_ENREF_35)].

PCR-based detection of CTCs has evolved remarkably, especially after the introduction of the quantitative RT-PCR (qRT-PCR) technique, which can minimize possible false-positive results by using a certain “cutoff value” during the analysis process. Identification of appropriate DNA/RNA-based markers expressed by CTCs is considered critical in order to enhance the specificity and reliability of its detection. Therefore, conventional markers for CTCs, such as CKs and CEA, and other diverse markers have been investigated towards their possible clinical application in several malignancies[[38](#_ENREF_38)]. CTC-related markers and the introduction of profile analysis including microRNAs (miRNAs) features also might be useful to resolve these issues[[39-41](#_ENREF_39)].

***CTC detection in patients with GC and its clinical relevance***

To date, many researchers have tried to detect CTCs in patients with GC and demonstrated its relevance to biological and oncogenic functions using various approaches. Table 1 represents a summary of previous reports, especially focusing on methodologies, targeted molecules and detection rates. Since its introduction, RT-PCR technology has become the most widely used approach to achieve a satisfactory detection rate despite the extremely low concentration of CTCs in the bloodstream. However, a high sensitivity of RT-PCR may cause an increase in false positive detection even in healthy controls. Therefore, some researchers have utilized multiple detection markers in an mRNA-based assay and suggested its potent usefulness[[42-44](#_ENREF_42)]. Of particular note, Wu *et al*[[44](#_ENREF_44)] have developed a sensitive assay using a high-throughput colorimetric membrane array, in which multiple markers, such as human telomerase reverse transcriptase (TERT), cytokeratin 19 (CK19), CEA and MUC1, are measured simultaneously and the combination of four markers serves as a prognostic indicator for overall survival and postoperative recurrence/metastasis in GC. Recently, non-coding RNAs, such as miRNAs and Piwi-interacting RNAs (piRNAs), have been proven to alter their expression in carcinogenesis and tumor progression[[45-47](#_ENREF_45)], so these cancer-specific alterations have been reported to be useful for the detection of CTCs in GC[[48-52](#_ENREF_48)]. However, some of those reports, in which a mononuclear cell layer was used to isolate total RNA, may not reflect miRNAs originating only from CTCs because the possibility of contamination by leukocyte-originated RNAs cannot be excluded. The presence of miRNAs originating from peripheral blood cells has been demonstrated in the blood of both cancer patients and normal individuals, and furthermore, contamination from those miRNAs has been observed even for circulating cell-free miRNA analysis[[53](#_ENREF_53),[54](#_ENREF_54)]. Those issues should be addressed before proceeding to clinical practice, and moreover, exhaustive exploration to identify more sensitive miRNA/piRNA-related markers might be desirable to achieve an accurate assay.

Recurrence and metastasis are the most critical factors not only for predicting clinical outcome but also for the quality of life in patients with GC. As summarized in Table 2, accumulating reports have suggested the significance of CTC detection as a prognostic indicator by various approaches, including both the CellSearch System and RT-PCR/ qRT-PCR methods. Hiraiwa *et al*[[55](#_ENREF_55)] examined CTCs in 130 gastrointestinal cancer patients involving 44 GC patients using the CellSearch System. Their results demonstrated that the metastatic GC patients with ≥ 2 CTCs (*n* = 15) had a significantly shorter overall survival rate than the metastatic GC patients with < 2 CTCs (*n* = 12) (*P* = 0.039). In a prospective study, Matsusaka *et al*[[56](#_ENREF_56)] also evaluated the relevance of CTCs to chemotherapy and clinical outcome using the CellSearch System. Their results showed that GC patients with ≥ 4 CTCs at 2 and 4 wk after the initiation of chemotherapy had significantly shorter overall survival and progression-free survival in comparison with GC patients with < 4 CTCs, whereas CTC status at baseline (*i.e.*, before the initiation of chemotherapy) had no statistical association with clinical outcomes. These findings may imply the close relationship of CTC status and treatment response.

 The majority of the studies using RT-PCR/qRT-PCR methods, which are also widely used for prognosis analysis, have relatively small numbers of cases. Under such circumstances, Mimori *et al*[[57](#_ENREF_57)] focused on one candidate marker, membrane type 1 matrix metalloproteinase (MT1-MMP) mRNA levels, based on results from cDNA microarray analysis, and consequently validated its relevance in a subsequent qRT-PCR based study involving more than 800 GC patients. As a result, MT1-MMP mRNA levels in peripheral blood were indicated to be an independent factor for determining recurrence and distant metastasis of GC (*P* = 0.0018).

Intriguingly, some groups have reported time-dependent changes in the detection rate of CTCs during the peri-operative time course[[58-61](#_ENREF_58)]. Those changes may imply the possibility of monitoring the tumor dynamics; however, the biological and clinical meaning of CTCs still remains unknown and controversial. In fact, incompatible events, including both increase and decrease in CTC detection rates during surgical maneuvers, have been proposed so far[[58-61](#_ENREF_58)]. This discrepancy might be partially explained by a wide variety of measurement parameters, from the methodology itself to targeted markers, patient background/properties and sample conditions.

In summary, recent technological advances have provided considerable progress and interest in the detection of CTCs in various cancers, including GC. Although previous studies have shown a potent usefulness of CTC detection as a novel diagnostic and prognostic assay in cancer patients, little remains known about the biological features and fundamental roles of these cells. Detailed characterization of CTCs and well-designed experiments should resolve current underlying issues and provide the opportunity for clinical impact in cancer therapy.

**BIOLOGY AND DETECTION OF CELL-FREE NUCLEIC ACIDS**

The study of cfNAs has a considerably long history since it was first reported in 1948 by Mandel and Metais[[62](#_ENREF_62)], who successfully detected nucleic acids in human plasma. Unfortunately, their work attracted little attention at that time owing to a lack of sufficient understanding of that innovative concept. Regarding malignant disease, in 1977, Leon *et al*[[63](#_ENREF_63)] first reported the presence of cell-free DNA (cfDNA) in the serum of cancer patients. Furthermore, they also mentioned its potent function as a clinical indicator, showing decreased cfDNA levels in response to radiotherapy. In 1989, Stroun *et al*[[64](#_ENREF_64)] successfully detected cfDNA with neoplastic characteristics and proposed the first evidence suggesting that tumors can shed DNA into the circulation. This hypothesis was further strengthened by two studies in 1994, in which NRAS mutations in the plasma of patients with myelodysplastic syndrome or acute myelogenous leukemia, and KRAS mutations in the plasma or serum of patients with pancreatic cancer[[65](#_ENREF_65)], were detected. Those findings opened up a new field in the exploration of circulating nucleic acids, and many meritorious studies have demonstrated the biological function of cfNAs and their potential as novel biomarkers regarding DNA, mRNA and miRNAs (Figure 1).

In regard to the origin of circulating nucleic acids, two main potent release mechanisms, called “passive” and “active”, are advocated to date. The passive mechanism involves the release of nucleic acids originated from apoptotic and necrotic cells into the bloodstream. Macrophages and phagocytes play an important role in phagocytosis of necrotic and apoptotic cells and can release digested nucleic acids into the microenvironment[[66](#_ENREF_66),[67](#_ENREF_67)]. In contrast, it is reported that fragments of cellular nucleic acids can be actively released[[68](#_ENREF_68),[69](#_ENREF_69)]. Although the active secretion into the circulation remains enigmatic, one potential explanation is that cancer cells would release nucleic acids to transform the targeted recipient cells at distant locations[[70-72](#_ENREF_70)]. In addition to those two mechanisms, cfNAs might be released by CTCs, however, there appears to be a huge gap between the amount of cfNAs and the rarity of CTCs in the bloodstream as described in the previous section. Thus, this hypothesis has been controversial so far.

***Circulating cell-free DNA in plasma/serum***

The study of circulating cfDNA in the plasma/serum involves the measurement of the total volume of circulating DNA as well as the detection of cancer-related genetic/ epigenetic aberrations, which include microsatellite instability, loss of heterozygosity, genetic polymorphisms, point mutations, methylation, deletion/amplification/ translocation of chromosome and integrity (*i.e.*, the ratio of longer DNA fragment to shorter one based on the different cleavage process between apoptosis and necrosis[[73](#_ENREF_73)]). The latter approach is generally recognized to be able to cover a wider range of oncogenic alterations in various cancers and to possess more potent application in the clinical setting than the former one, partly because cfDNA can be released into the bloodstream and is detectable in the plasma/serum in healthy humans[[69](#_ENREF_69),[74](#_ENREF_74)]. In fact, numerous reports have demonstrated the detection of genetic and epigenetic alterations in circulating DNA in the plasma/serum in cancer patients[[75-79](#_ENREF_75)]. Furthermore, in colorectal cancer, recent two reports clearly demonstrated a correlation between acquired resistance to the anti-EGFR antibody drugs, such as cetuximab and panitumumab, and the emergence of KRAS mutations, which was successfully detected and monitored in the blood of patients under treatment[[80](#_ENREF_80),[81](#_ENREF_81)]. Misale *et al*[[81](#_ENREF_81)] also indicated the potential of cfDNA to monitor tumor dynamics more sensitively compared to conventional assays, showing that KRAS mutant alleles were confirmed in the blood of a cetuximab-treated patient 10 months earlier than radiographic examinations. Moreover, Leary *et al*[[82](#_ENREF_82)] have recently analyzed individual tumor-specific DNA translocations in paired solid tumor and circulating cfDNA samples using next-generation sequencing technology and consequently demonstrated the feasibility of personalized biomarkers, enabling a so-called “tailor-made” therapeutic strategy. In summary, moving toward the development and future application in the clinical setting, the accumulated evidence has proven the potent usefulness of cfDNA for the detection of disease as well as for the assessment of residual disease, recurrence, and secondary resistance.

***Detection of circulating DNA in patients with GC and its clinical relevance***

Previous reports regarding circulating cfDNA in GC patients are summarized inTable 3. Among those reports, a few studies with respect to the concentration of circulating cfDNA are found, in which a housekeeping gene, beta-actin[[83](#_ENREF_83)], and a non-coding genomic DNA repeat sequence, ALU[[84](#_ENREF_84)], were evaluated. In contrast, the detection of methylated DNA in plasma/serum appears to be the most widely used approach in GC, which was usually investigated by methylation specific-PCR (MSP) or quantitative methylation specific-PCR (qMSP) assays. In 2002, Lee *et al*[[85](#_ENREF_85)] first reported the potent application of detecting methylated DNA of DAP-kinase, E-cadherin, GSTP1, p15 and p16 in the serum of GC patients. Thereafter, technological advances and the exploration of more sensitive and specific genes have provided the accumulated evidence in this field. In detail, comprehensive analyses by methylation CpG island microarray have suggested the possibility of more significant genes for detecting methylated DNA[[86](#_ENREF_86),[87](#_ENREF_87)]. Most recently, Ling *et al*[[88](#_ENREF_88)] clearly demonstrated the potent usefulness of detecting methylated XAF1 DNA as a diagnostic as well as prognostic biomarker with satisfactory degrees of specificity and sensitivity. Specifically, methylated XAF1 DNA in serum was detected in 69.8% (141/202) of the GC patients and none of the healthy individuals (0/88) with an AUC of 0.909 in a ROC curve analysis for discrimination of the two groups and was significantly correlated with poorer prognosis in GC (*P* < 0.001, disease-free survival, Kaplan-Meier survival curves, Log-rank test).

Concerning genetic alterations in other types of cancers, the relationships with tumor-specific gene alteration such as HER2 in breast cancer[[89](#_ENREF_89)] and APC in colorectal cancer[[75](#_ENREF_75),[90](#_ENREF_90)] have been revealed even in circulating cfDNA. In GC, Park *et al*[[91](#_ENREF_91)] investigated gene amplification of MYC in the plasma of GC patients and showed that the plasma MYC/GAPDH ratio was significantly higher in the GC patients than that in the healthy controls (*P* < 0.001) and correlated with the tissue MYC/GAPDH ratio (*P* = 0.009), and tissue MYC status by FISH (*P* = 0.024). In contrast, among GC patients with a 2+ or 3+ score in a HER2 IHC assay, Lee *et al*[[92](#_ENREF_92)] reported that no significant association was observed between the HER2 level in plasma and the copy number variation in tumor tissue determined by FISH. Although it is unclear why there was a discrepancy between these two results, it may be partially explained by the inappropriate employment of reference genes and the heterogeneity of GC tissues. The investigation of circulating cfDNA relating to genetic aberration in GC remains in its infancy. Therefore, further evidence is expected to address current controversial issues and develop this field.

***Circulating cell-free mRNA in plasma/serum***

The presence of RNase in plasma/serum had long been known, and furthermore, the RNase concentration in serum was reported to be elevated in cancer patients in the 1970s[[93](#_ENREF_93),[94](#_ENREF_94)]. Given that mRNA in plasma/serum might be more fragile than DNA and susceptible to degradation by RNase, it was not clear whether mRNA could exist in plasma/serum with sufficient integrity to allow amplification, although several reports had previously suggested the possible presence of RNA in serum forming a complex with proteolipids[[95](#_ENREF_95),[96](#_ENREF_96)]. In 1999, two groups reported the successful detection of cell-free RNA such as tyrosinase mRNA in serum of patients with malignant melanoma[[97](#_ENREF_97)] and EBV-associated RNA associated in plasma of patients with nasopharyngeal carcinoma[[98](#_ENREF_98)]. Subsequently, many studies have demonstrated the presence of specific mRNA in plasma/serum and its potent clinical relevance in patients with a variety of cancers[[99-101](#_ENREF_99)]. At present, it is considered that mRNA in plasma/serum may be protected from degradation by packaging in secretory membrane vesicles, such as exosomes, microvesicles and multivesicles, which are released from cellular surfaces into the bloodstream[[102](#_ENREF_102),[103](#_ENREF_103)].

***Circulating cell-free miRNA in plasma/serum***

In the past decade, circulating cell-free miRNAs in plasma/serum have attracted increasing attention among investigators in various types of research field including oncology. The discovery of miRNA dates back to 1993, when Lee *et al*[[104](#_ENREF_104)] found that a short RNA product encoded by the *lin-4* gene inhibited the translation of its putative target, *lin-14* mRNA, with partial sequence complementarity during a study of *Caenorhabditis elegans (C. elegans)* development. In 2000, a second miRNA, *let-7*, was identified to repress the functions of multiple mRNAs in *C. elegans*[[105](#_ENREF_105)]. Subsequently, let-7 was found to be widely conserved across species, implying the ubiquitous roles of miRNAs[[106](#_ENREF_106)]. Since then, accumulated research has revealed their biological features in a variety of diseases.

In summary, miRNAs are a group of noncoding small RNAs, whose mature form generally consists of 19-25 nucleotides. miRNAs are involved in post-translational regulation of gene expression by inhibiting stability and translation of mRNAs[[107](#_ENREF_107)]. To date, more than 1800 miRNAs have been characterized in *Homo sapiens* according to the miRNA database (miRBase), and the number of listed miRNAs is increasing. It is suggested that one miRNA can regulate multiple different mRNAs, and conversely one mRNA can be regulated by multiple miRNAs[[108](#_ENREF_108),[109](#_ENREF_109)].

Concerning malignant diseases, miRNAs have been demonstrated to play essential roles in cell proliferation, cell differentiation, apoptosis, EMT, and metastasis[[45](#_ENREF_45),[46](#_ENREF_46)]. Numerous studies have proven the aberrant expression of miRNA and its critical characteristics including both oncogenic and tumor suppressive functions in various cancers. Those findings have motivated us to accelerate this promising field to the next stage, such as development of miRNA-based biomarkers and therapies[[110](#_ENREF_110),[111](#_ENREF_111)].

In 2008, the successful detection of circulating miRNAs and their significance in malignant diseases were first reported by several groups[[112-115](#_ENREF_112)]. Notably, Mitchell *et al*[[112](#_ENREF_112)] and Chen *et al*[[113](#_ENREF_113)] clearly demonstrated the biological features and potent utility of circulating miRNA, showing their high stability and reproducibility with resistance to endogenous/exogenous RNase, prolonged incubation at room temperature, extreme pH conditions and multiple freeze–thawing processes. The stability of miRNA in plasma/serum, likely greater than that of mRNA, could be explained by some protective mechanisms, which involve packaging in secretory particles (apoptotic bodies, exosomes *etc.*)[[72](#_ENREF_72),[116](#_ENREF_116)] and binding to certain proteins (Argonatute2, High-density Lipoproteins, *etc.*)[[117-119](#_ENREF_117)]. Furthermore, secretory vesicles including miRNAs have been shown to be able to function as intercellular transmitters[[72](#_ENREF_72),[116](#_ENREF_116),[120](#_ENREF_120)], suggesting that circulating miRNAs in plasma/serum possess various roles in cancer development and metastasis. Those findings have provided new insight into the screening and monitoring of cancer patients, and emerging evidence has suggested the promising potential of circulating miRNA as a novel and non-invasive biomarker in clinical practice[[121](#_ENREF_121),[122](#_ENREF_122)].

***Detection of circulating cell-free RNA in patients with GC and its clinical relevance***

As summarized in Table 4, the number of previous reports regarding circulating mRNA in GC patients is small compared with those regarding other types of cancers and with those concerning circulating DNA in GC. However, as Kang *et al*[[123](#_ENREF_123)] recently reported that the detection of plasma hTERT mRNA can serve as a potential marker for diagnosis and prognosis of GC patients, increased insight and evidence about circulating mRNA might facilitate the development of this field.

Since the potent utility of determining miRNAs in the plasma of GC patients was first reported by our group in 2010[[124](#_ENREF_124)], many studies have demonstrated the significance of circulating miRNAs as novel biomarkers (Table 5). Still, the immaturity of the field has led to several issues concerning its actual introduction in clinical settings. To date, there has been no consensus regarding how inter- and intra-individual variations can affect the results, which sample (*i.e.*, plasma or serum) is more favorable for measuring circulating miRNA, or which molecule is the most appropriate for the sensitive detection and endogenous controls. Moreover, as mentioned before, one miRNA can regulate multiple mRNAs and the numbers of discovered miRNAs and targeted mRNAs are still increasing owing to recent advances in bioinformatic analysis, making it more difficult to obtain a meticulous understanding of each miRNA. Although comprehensive approaches by genome-wide profiling can address those problems to some extent, a further large-scale validation with well-established methods seems to be required in this area as well.

To overcome obstacles due to inter-individual variations, our group tried to identify candidate miRNAs by comparing miRNA profiles between pre- and post-operative samples in the same individuals[[125](#_ENREF_125)]. Because miRNAs are involved in various non-cancerous cell biology including physiological modulation and pathological disruption of basic pathways[[126](#_ENREF_126),[127](#_ENREF_127)], the existence of inter-individual differences can be strongly suspected based on miRNA expression. As a result, two miRNAs, miR-451 and miR-486, were selected based on this strategy and their significant value in discriminating between GC patients and healthy controls was clearly demonstrated with an AUC of 0.96 and 0.92 in ROC curve analysis for miR-451 and miR-486, respectively. We suggest that the miRNAs isolated by these concepts could be valuable biomarkers for the effective detection of early cancer and recurrence because the change of these miRNAs can be affected by the reduction of the volume of cancer tissue and is therefore directly related to tumor existence.

Most recently, our group published new observations in which long non-coding RNAs (lncRNAs) in the plasma of GC patients were successfully detected[[128](#_ENREF_128)]. Specifically, three lncRNAs (H19, HOX antisense intergenic RNA and metastasis associated lung adenocarcinoma transcript-1) stably exist in plasma from both GC patients and healthy controls. Plasma H19 levels were significantly higher in the patient group than the control group and decreased postoperatively, implying the possible use of H19 levels as a novel diagnostic marker in GC. LncRNAs are defined as non-protein coding transcripts longer than 200 nt lacking significant open reading frames and involved in fundamental cellular processes, such as RNA processing, gene regulation, chromatin modification, gene transcription, and post-transcriptional gene regulation based on RNA sequence complementary interactions[[129](#_ENREF_129),[130](#_ENREF_130)]. Detailed investigations have shown that lncRNAs can exhibit developmental and tissue specific expression patterns as well as aberrant regulation in a variety of diseases, including GC[[131](#_ENREF_131),[132](#_ENREF_132)]. Explorations of a novel type of RNA can provide more intriguing aspects in this research field.

**CONCLUSION**

Although the concept of “liquid biopsy” possesses great potential in detection and monitoring of diseases as previously described in detail, several hurdles should be overcome before translating it into clinical settings. One of the most important issues is the lack of consensus in technical approaches, which involves various aspects of the methodologies, such as preferable sample type, storage conditions, candidate molecules and suitable detection techniques. Moreover, technical errors may introduce contaminated cells or molecules into experimental samples, which could cause misunderstandings and statistical errors. Therefore, the standardization of techniques throughout all experimental steps should be emphasized.

Owing to recent remarkable technological developments, novel revolutionary approaches including an *in vivo* CTC isolation system[[32](#_ENREF_32)] and multi-detectable array have been introduced into this research field. However, some issues raised by those advances should be addressed properly. Although multi-detection approaches can facilitate exhaustive screenings and provide us with various types of information, the important considerations are which molecules should be selected as a tumor marker and how the result of an individual patient obtained by multiple detection panels should be effectively utilized. Of course, the cost and practicality of each assay should also be taken into consideration to some extent.

In summary, the science of CTCs and circulating cfNAs remains in its infancy. Despite numerous approaches and techniques that have been advocated to accomplish the ultimate goal, that is, the development of a useful, sensitive and real-time monitoring system from the blood, few proposals have been translated into clinical practice. Large-scale studies and further understanding of their biology and significance could resolve those problems and enhance their utility as biomarkers. Consequently, the development of novel biomarkers based on CTCs and cfNAs could provide many benefits for cancer patients including the improvement of clinical outcomes in the near future.

**REFERENCES**

1 **Jemal A**, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011; **61**: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]

2 **Alix-Panabières C**, Pantel K. Circulating tumor cells: liquid biopsy of cancer. *Clin Chem* 2013; **59**: 110-118 [PMID: 23014601 DOI: 10.1373/clinchem.2012.194258]

3 **van de Stolpe A**, Pantel K, Sleijfer S, Terstappen LW, den Toonder JM. Circulating tumor cell isolation and diagnostics: toward routine clinical use. *Cancer Res* 2011; **71**: 5955-5960 [PMID: 21896640 DOI: 10.1158/0008-5472.CAN-11-1254]

4 **Crowley E**, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. *Nat Rev Clin Oncol* 2013; **10**: 472-484 [PMID: 23836314 DOI: 10.1038/nrclinonc.2013.110]

5 **Schwarzenbach H**, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. *Nat Rev Cancer* 2011; **11**: 426-437 [PMID: 21562580 DOI: 10.1038/nrc3066]

6 **Ashworth T**. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. *Aust Med J* 1869; **14**: 146-149

7 **Ghossein RA**, Bhattacharya S, Rosai J. Molecular detection of micrometastases and circulating tumor cells in solid tumors. *Clin Cancer Res* 1999; **5**: 1950-1960 [PMID: 10473071]

8 **Allard WJ**, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. *Clin Cancer Res* 2004; **10**: 6897-6904 [PMID: 15501967 DOI: 10.1158/1078-0432.CCR-04-0378]

9 **Zheng S**, Lin H, Liu JQ, Balic M, Datar R, Cote RJ, Tai YC. Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. *J Chromatogr A* 2007; **1162**: 154-161 [PMID: 17561026 DOI: 10.1016/j.chroma.2007.05.064]

10 **Vona G**, Sabile A, Louha M, Sitruk V, Romana S, Schütze K, Capron F, Franco D, Pazzagli M, Vekemans M, Lacour B, Bréchot C, Paterlini-Bréchot P. Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells. *Am J Pathol* 2000; **156**: 57-63 [PMID: 10623654 DOI: 10.1016/S0002-9440(10)64706-2]

11 **Coumans FA**, van Dalum G, Beck M, Terstappen LW. Filter characteristics influencing circulating tumor cell enrichment from whole blood. *PLoS One* 2013; **8**: e61770 [PMID: 23626725 DOI: 10.1371/journal.pone.0061770]

12 **Coumans FA**, van Dalum G, Beck M, Terstappen LW. Filtration parameters influencing circulating tumor cell enrichment from whole blood. *PLoS One* 2013; **8**: e61774 [PMID: 23658615 DOI: 10.1371/journal.pone.0061774]

13 **Marrinucci D**, Bethel K, Bruce RH, Curry DN, Hsieh B, Humphrey M, Krivacic RT, Kroener J, Kroener L, Ladanyi A, Lazarus NH, Nieva J, Kuhn P. Case study of the morphologic variation of circulating tumor cells. *Hum Pathol* 2007; **38**: 514-519 [PMID: 17188328 DOI: 10.1016/j.humpath.2006.08.027]

14 **Tan SJ**, Yobas L, Lee GY, Ong CN, Lim CT. Microdevice for the isolation and enumeration of cancer cells from blood. *Biomed Microdevices* 2009; **11**: 883-892 [PMID: 19387837 DOI: 10.1007/s10544-009-9305-9]

15 **Mohamed H**, Murray M, Turner JN, Caggana M. Isolation of tumor cells using size and deformation. *J Chromatogr A* 2009; **1216**: 8289-8295 [PMID: 19497576 DOI: 10.1016/j.chroma.2009.05.036]

16 **Munz M**, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling. *Cancer Res* 2009; **69**: 5627-5629 [PMID: 19584271 DOI: 10.1158/0008-5472.CAN-09-0654]

17 **van der Gun BT**, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, Rots MG. EpCAM in carcinogenesis: the good, the bad or the ugly. *Carcinogenesis* 2010; **31**: 1913-1921 [PMID: 20837599 DOI: 10.1093/carcin/bgq187]

18 **Wenqi D**, Li W, Shanshan C, Bei C, Yafei Z, Feihu B, Jie L, Daiming F. EpCAM is overexpressed in gastric cancer and its downregulation suppresses proliferation of gastric cancer. *J Cancer Res Clin Oncol* 2009; **135**: 1277-1285 [PMID: 19294417 DOI: 10.1007/s00432-009-0569-5]

19 **Cristofanilli M**, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. *N Engl J Med* 2004; **351**: 781-791 [PMID: 15317891 DOI: 10.1056/NEJMoa040766]

20 **Danila DC**, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. *Clin Cancer Res* 2007; **13**: 7053-7058 [PMID: 18056182 DOI: 10.1158/1078-0432.CCR-07-1506]

21 **Hayes DF**, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. *Clin Cancer Res* 2006; **12**: 4218-4224 [PMID: 16857794 DOI: 10.1158/1078-0432.CCR-05-2821]

22 **Riethdorf S**, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Jänicke F, Jackson S, Gornet T, Cristofanilli M, Pantel K. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. *Clin Cancer Res* 2007; **13**: 920-928 [PMID: 17289886 DOI: 10.1158/1078-0432.CCR-06-1695]

23 **Sastre J**, Maestro ML, Puente J, Veganzones S, Alfonso R, Rafael S, García-Saenz JA, Vidaurreta M, Martín M, Arroyo M, Sanz-Casla MT, Díaz-Rubio E. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. *Ann Oncol* 2008; **19**: 935-938 [PMID: 18212090 DOI: 10.1093/annonc/mdm583]

24 **Shaffer DR**, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, Anand A, Smith K, Maslak P, Doyle GV, Terstappen LW, Lilja H, Heller G, Fleisher M, Scher HI. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. *Clin Cancer Res* 2007; **13**: 2023-2029 [PMID: 17404082 DOI: 10.1158/1078-0432.CCR-06-2701]

25 **Thompson EW**, Haviv I. The social aspects of EMT-MET plasticity. *Nat Med* 2011; **17**: 1048-1049 [PMID: 21900919 DOI: 10.1038/nm.2437]

26 **Maheswaran S**, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, Digumarthy S, Muzikansky A, Irimia D, Settleman J, Tompkins RG, Lynch TJ, Toner M, Haber DA. Detection of mutations in EGFR in circulating lung-cancer cells. *N Engl J Med* 2008; **359**: 366-377 [PMID: 18596266 DOI: 10.1056/NEJMoa0800668]

27 **Nagrath S**, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M. Isolation of rare circulating tumour cells in cancer patients by microchip technology. *Nature* 2007; **450**: 1235-1239 [PMID: 18097410 DOI: 10.1038/nature06385]

28 **Stott SL**, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, Moore AL, Tsukrov DI, Kempner ME, Dahl DM, Wu CL, Iafrate AJ, Smith MR, Tompkins RG, Sequist LV, Toner M, Haber DA, Maheswaran S. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. *Sci Transl Med* 2010; **2**: 25ra23 [PMID: 20424012 DOI: 10.1126/scitranslmed.3000403]

29 **Sakaizawa K**, Goto Y, Kiniwa Y, Uchiyama A, Harada K, Shimada S, Saida T, Ferrone S, Takata M, Uhara H, Okuyama R. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. *Br J Cancer* 2012; **106**: 939-946 [PMID: 22281663 DOI: 10.1038/bjc.2012.12]

30 **Heitzer E**, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM, Lax S, Waldispuehl-Geigl J, Mauermann O, Lackner C, Höfler G, Eisner F, Sill H, Samonigg H, Pantel K, Riethdorf S, Bauernhofer T, Geigl JB, Speicher MR. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. *Cancer Res* 2013; **73**: 2965-2975 [PMID: 23471846 DOI: 10.1158/0008-5472.can-12-4140]

31 **Cann GM**, Gulzar ZG, Cooper S, Li R, Luo S, Tat M, Stuart S, Schroth G, Srinivas S, Ronaghi M, Brooks JD, Talasaz AH. mRNA-Seq of single prostate cancer circulating tumor cells reveals recapitulation of gene expression and pathways found in prostate cancer. *PLoS One* 2012; **7**: e49144 [PMID: 23145101 DOI: 10.1371/journal.pone.0049144]

32 **Saucedo-Zeni N**, Mewes S, Niestroj R, Gasiorowski L, Murawa D, Nowaczyk P, Tomasi T, Weber E, Dworacki G, Morgenthaler NG, Jansen H, Propping C, Sterzynska K, Dyszkiewicz W, Zabel M, Kiechle M, Reuning U, Schmitt M, Lücke K. A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. *Int J Oncol* 2012; **41**: 1241-1250 [PMID: 22825490 DOI: 10.3892/ijo.2012.1557]

33 **Krivacic RT**, Ladanyi A, Curry DN, Hsieh HB, Kuhn P, Bergsrud DE, Kepros JF, Barbera T, Ho MY, Chen LB, Lerner RA, Bruce RH. A rare-cell detector for cancer. *Proc Natl Acad Sci U S A* 2004; **101**: 10501-10504 [PMID: 15249663 DOI: 10.1073/pnas.0404036101]

34 **Hsieh HB**, Marrinucci D, Bethel K, Curry DN, Humphrey M, Krivacic RT, Kroener J, Kroener L, Ladanyi A, Lazarus N, Kuhn P, Bruce RH, Nieva J. High speed detection of circulating tumor cells. *Biosens Bioelectron* 2006; **21**: 1893-1899 [PMID: 16464570 DOI: 10.1016/j.bios.2005.12.024]

35 **Alix-Panabières C**. EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients. *Recent Results Cancer Res* 2012; **195**: 69-76 [PMID: 22527495 DOI: 10.1007/978-3-642-28160-0\_6]

36 **Alix-Panabières C**, Vendrell JP, Pellé O, Rebillard X, Riethdorf S, Müller V, Fabbro M, Pantel K. Detection and characterization of putative metastatic precursor cells in cancer patients. *Clin Chem* 2007; **53**: 537-539 [PMID: 17327507 DOI: 10.1373/clinchem.2006.079509]

37 **Alix-Panabières C**, Vendrell JP, Slijper M, Pellé O, Barbotte E, Mercier G, Jacot W, Fabbro M, Pantel K. Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. *Breast Cancer Res* 2009; **11**: R39 [PMID: 19549321 DOI: 10.1186/bcr2326]

38 **Pantel K**, Alix-Panabières C, Riethdorf S. Cancer micrometastases. *Nat Rev Clin Oncol* 2009; **6**: 339-351 [PMID: 19399023 DOI: 10.1038/nrclinonc.2009.44]

39 **Sieuwerts AM**, Mostert B, Bolt-de Vries J, Peeters D, de Jongh FE, Stouthard JM, Dirix LY, van Dam PA, Van Galen A, de Weerd V, Kraan J, van der Spoel P, Ramírez-Moreno R, van Deurzen CH, Smid M, Yu JX, Jiang J, Wang Y, Gratama JW, Sleijfer S, Foekens JA, Martens JW. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. *Clin Cancer Res* 2011; **17**: 3600-3618 [PMID: 21505063 DOI: 10.1158/1078-0432.CCR-11-0255]

40 **Smirnov DA**, Zweitzig DR, Foulk BW, Miller MC, Doyle GV, Pienta KJ, Meropol NJ, Weiner LM, Cohen SJ, Moreno JG, Connelly MC, Terstappen LW, O'Hara SM. Global gene expression profiling of circulating tumor cells. *Cancer Res* 2005; **65**: 4993-4997 [PMID: 15958538 DOI: 10.1158/0008-5472.CAN-04-4330]

41 **Sieuwerts AM**, Kraan J, Bolt-de Vries J, van der Spoel P, Mostert B, Martens JW, Gratama JW, Sleijfer S, Foekens JA. Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. *Breast Cancer Res Treat* 2009; **118**: 455-468 [PMID: 19115104 DOI: 10.1007/s10549-008-0290-0]

42 **Uen YH**, Lin SR, Wu CH, Hsieh JS, Lu CY, Yu FJ, Huang TJ, Wang JY. Clinical significance of MUC1 and c-Met RT-PCR detection of circulating tumor cells in patients with gastric carcinoma. *Clin Chim Acta* 2006; **367**: 55-61 [PMID: 16403482 DOI: 10.1016/j.cca.2005.11.013]

43 **Wu CH**, Lin SR, Hsieh JS, Chen FM, Lu CY, Yu FJ, Cheng TL, Huang TJ, Huang SY, Wang JY. Molecular detection of disseminated tumor cells in the peripheral blood of patients with gastric cancer: evaluation of their prognostic significance. *Dis Markers* 2006; **22**: 103-109 [PMID: 16788243]

44 **Wu CH**, Lin SR, Yu FJ, Wu DC, Pan YS, Hsieh JS, Huang SY, Wang JY. Development of a high-throughput membrane-array method for molecular diagnosis of circulating tumor cells in patients with gastric cancers. *Int J Cancer* 2006; **119**: 373-379 [PMID: 16477642 DOI: 10.1002/ijc.21856]

45 **Lu J**, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles classify human cancers. *Nature* 2005; **435**: 834-838 [PMID: 15944708 DOI: 10.1038/nature03702]

46 **Croce CM**. Causes and consequences of microRNA dysregulation in cancer. *Nat Rev Genet* 2009; **10**: 704-714 [PMID: 19763153 DOI: 10.1038/nrg2634]

47 **Mei Y**, Clark D, Mao L. Novel dimensions of piRNAs in cancer. *Cancer Lett* 2013; **336**: 46-52 [PMID: 23603435 DOI: 10.1016/j.canlet.2013.04.008]

48 **Zhou H**, Guo JM, Lou YR, Zhang XJ, Zhong FD, Jiang Z, Cheng J, Xiao BX. Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. *J Mol Med (Berl)* 2010; **88**: 709-717 [PMID: 20349219 DOI: 10.1007/s00109-010-0617-2]

49 **Cui L**, Lou Y, Zhang X, Zhou H, Deng H, Song H, Yu X, Xiao B, Wang W, Guo J. Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using piRNAs as markers. *Clin Biochem* 2011; **44**: 1050-1057 [PMID: 21704610 DOI: 10.1016/j.clinbiochem.2011.06.004]

50 **Zheng Y**, Cui L, Sun W, Zhou H, Yuan X, Huo M, Chen J, Lou Y, Guo J. MicroRNA-21 is a new marker of circulating tumor cells in gastric cancer patients. *Cancer Biomark* 2011; **10**: 71-77 [PMID: 22430134 DOI: 10.3233/CBM-2011-0231]

51 **Valladares-Ayerbes M**, Reboredo M, Medina-Villaamil V, Iglesias-Díaz P, Lorenzo-Patiño MJ, Haz M, Santamarina I, Blanco M, Fernández-Tajes J, Quindós M, Carral A, Figueroa A, Antón-Aparicio LM, Calvo L. Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. *J Transl Med* 2012; **10**: 186 [PMID: 22954417 DOI: 10.1186/1479-5876-10-186]

52 **Zhou H**, Xiao B, Zhou F, Deng H, Zhang X, Lou Y, Gong Z, Du C, Guo J. MiR-421 is a functional marker of circulating tumor cells in gastric cancer patients. *Biomarkers* 2012; **17**: 104-110 [PMID: 22263628 DOI: 10.3109/1354750X.2011.614961]

53 **Duttagupta R**, Jiang R, Gollub J, Getts RC, Jones KW. Impact of cellular miRNAs on circulating miRNA biomarker signatures. *PLoS One* 2011; **6**: e20769 [PMID: 21698099 DOI: 10.1371/journal.pone.0020769]

54 **Pritchard CC**, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, Tait JF, Tewari M. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. *Cancer Prev Res (Phila)* 2012; **5**: 492-497 [PMID: 22158052 DOI: 10.1158/1940-6207.capr-11-0370]

55 **Hiraiwa K**, Takeuchi H, Hasegawa H, Saikawa Y, Suda K, Ando T, Kumagai K, Irino T, Yoshikawa T, Matsuda S, Kitajima M, Kitagawa Y. Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers. *Ann Surg Oncol* 2008; **15**: 3092-3100 [PMID: 18766405 DOI: 10.1245/s10434-008-0122-9]

56 **Matsusaka S**, Chìn K, Ogura M, Suenaga M, Shinozaki E, Mishima Y, Terui Y, Mizunuma N, Hatake K. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer. *Cancer Sci* 2010; **101**: 1067-1071 [PMID: 20219073 DOI: 10.1111/j.1349-7006.2010.01492.x]

57 **Mimori K**, Fukagawa T, Kosaka Y, Ishikawa K, Iwatsuki M, Yokobori T, Hirasaki S, Takatsuno Y, Sakashita H, Ishii H, Sasako M, Mori M. A large-scale study of MT1-MMP as a marker for isolated tumor cells in peripheral blood and bone marrow in gastric cancer cases. *Ann Surg Oncol* 2008; **15**: 2934-2942 [PMID: 18661187 DOI: 10.1245/s10434-008-9916-z]

58 **Ikeguchi M**, Kaibara N. Detection of circulating cancer cells after a gastrectomy for gastric cancer. *Surg Today* 2005; **35**: 436-441 [PMID: 15912289 DOI: 10.1007/s00595-004-2978-z]

59 **Miyazono F**, Natsugoe S, Takao S, Tokuda K, Kijima F, Aridome K, Hokita S, Baba M, Eizuru Y, Aikou T. Surgical maneuvers enhance molecular detection of circulating tumor cells during gastric cancer surgery. *Ann Surg* 2001; **233**: 189-194 [PMID: 11176124]

60 **Nishida S**, Kitamura K, Ichikawa D, Koike H, Tani N, Yamagishi H. Molecular detection of disseminated cancer cells in the peripheral blood of patients with gastric cancer. *Anticancer Res* 2000; **20**: 2155-2159 [PMID: 10928170]

61 **Pituch-Noworolska A**, Kolodziejczyk P, Kulig J, Drabik G, Szczepanik A, Czupryna A, Popiela T, Zembala M. Circulating tumour cells and survival of patients with gastric cancer. *Anticancer Res* 2007; **27**: 635-640 [PMID: 17348453]

62 **Mandel P**. Les acides nucleiques du plasma sanguin chez l'homme.*C R Seances Soc Biol Fil* 1948; **142**: 241-243 [PMID: 18875018]

63 **Leon SA**, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. *Cancer Res* 1977; **37**: 646-650 [PMID: 837366]

64 **Vasioukhin V**, Anker P, Maurice P, Lyautey J, Lederrey C, Stroun M. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. *Br J Haematol* 1994; **86**: 774-779 [PMID: 7918071]

65 **Sorenson GD**, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL. Soluble normal and mutated DNA sequences from single-copy genes in human blood. *Cancer Epidemiol Biomarkers Prev* 1994; **3**: 67-71 [PMID: 8118388]

66 **Choi JJ**, Reich CF, Pisetsky DS. The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells. *Immunology* 2005; **115**: 55-62 [PMID: 15819697 DOI: 10.1111/j.1365-2567.2005.02130.x]

67 **Pisetsky DS**, Fairhurst AM. The origin of extracellular DNA during the clearance of dead and dying cells. *Autoimmunity* 2007; **40**: 281-284 [PMID: 17516210 DOI: 10.1080/08916930701358826]

68 **Stroun M**, Lyautey J, Lederrey C, Mulcahy HE, Anker P. Alu repeat sequences are present in increased proportions compared to a unique gene in plasma/serum DNA: evidence for a preferential release from viable cells? *Ann N Y Acad Sci* 2001; **945**: 258-264 [PMID: 11708488]

69 **Stroun M**, Lyautey J, Lederrey C, Olson-Sand A, Anker P. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. *Clin Chim Acta* 2001; **313**: 139-142 [PMID: 11694251]

70 **Trejo-Becerril C**, Pérez-Cárdenas E, Taja-Chayeb L, Anker P, Herrera-Goepfert R, Medina-Velázquez LA, Hidalgo-Miranda A, Pérez-Montiel D, Chávez-Blanco A, Cruz-Velázquez J, Díaz-Chávez J, Gaxiola M, Dueñas-González A. Cancer progression mediated by horizontal gene transfer in an in vivo model. *PLoS One* 2012; **7**: e52754 [PMID: 23285175 DOI: 10.1371/journal.pone.0052754]

71 **García-Olmo DC**, Domínguez C, García-Arranz M, Anker P, Stroun M, García-Verdugo JM, García-Olmo D. Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of susceptible cultured cells. *Cancer Res* 2010; **70**: 560-567 [PMID: 20068178 DOI: 10.1158/0008-5472.CAN-09-3513]

72 **Kosaka N**, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. *J Biol Chem* 2010; **285**: 17442-17452 [PMID: 20353945 DOI: 10.1074/jbc.M110.107821]

73 **Wang BG**, Huang HY, Chen YC, Bristow RE, Kassauei K, Cheng CC, Roden R, Sokoll LJ, Chan DW, Shih IeM. Increased plasma DNA integrity in cancer patients. *Cancer Res* 2003; **63**: 3966-3968 [PMID: 12873992]

74 **Suzuki N**, Kamataki A, Yamaki J, Homma Y. Characterization of circulating DNA in healthy human plasma. *Clin Chim Acta* 2008; **387**: 55-58 [PMID: 17916343 DOI: 10.1016/j.cca.2007.09.001]

75 **Diehl F**, Li M, Dressman D, He Y, Shen D, Szabo S, Diaz LA, Goodman SN, David KA, Juhl H, Kinzler KW, Vogelstein B. Detection and quantification of mutations in the plasma of patients with colorectal tumors. *Proc Natl Acad Sci U S A* 2005; **102**: 16368-16373 [PMID: 16258065 DOI: 10.1073/pnas.0507904102]

76 **van 't Veer LJ**, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. *Nature* 2002; **415**: 530-536 [PMID: 11823860 DOI: 10.1038/415530a]

77 **Dawson SJ**, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, Rajan S, Humphray S, Becq J, Halsall D, Wallis M, Bentley D, Caldas C, Rosenfeld N. Analysis of circulating tumor DNA to monitor metastatic breast cancer. *N Engl J Med* 2013; **368**: 1199-1209 [PMID: 23484797 DOI: 10.1056/NEJMoa1213261]

78 **Chan KC**, Jiang P, Zheng YW, Liao GJ, Sun H, Wong J, Siu SS, Chan WC, Chan SL, Chan AT, Lai PB, Chiu RW, Lo YM. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. *Clin Chem* 2013; **59**: 211-224 [PMID: 23065472 DOI: 10.1373/clinchem.2012.196014]

79 **Castells A**, Puig P, Móra J, Boadas J, Boix L, Urgell E, Solé M, Capellà G, Lluís F, Fernández-Cruz L, Navarro S, Farré A. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. *J Clin Oncol* 1999; **17**: 578-584 [PMID: 10080602]

80 **Diaz LA**, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. *Nature* 2012; **486**: 537-540 [PMID: 22722843 DOI: 10.1038/nature11219]

81 **Misale S**, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. *Nature* 2012; **486**: 532-536 [PMID: 22722830 DOI: 10.1038/nature11156]

82 **Leary RJ**, Kinde I, Diehl F, Schmidt K, Clouser C, Duncan C, Antipova A, Lee C, McKernan K, De La Vega FM, Kinzler KW, Vogelstein B, Diaz LA, Velculescu VE. Development of personalized tumor biomarkers using massively parallel sequencing. *Sci Transl Med* 2010; **2**: 20ra14 [PMID: 20371490 DOI: 10.1126/scitranslmed.3000702]

83 **Sai S**, Ichikawa D, Tomita H, Ikoma D, Tani N, Ikoma H, Kikuchi S, Fujiwara H, Ueda Y, Otsuji E. Quantification of plasma cell-free DNA in patients with gastric cancer. *Anticancer Res* 2007; **27**: 2747-2751 [PMID: 17695442]

84 **Park JL**, Kim HJ, Choi BY, Lee HC, Jang HR, Song KS, Noh SM, Kim SY, Han DS, Kim YS. Quantitative analysis of cell-free DNA in the plasma of gastric cancer patients. *Oncol Lett* 2012; **3**: 921-926 [PMID: 22741019 DOI: 10.3892/ol.2012.592]

85 **Lee TL**, Leung WK, Chan MW, Ng EK, Tong JH, Lo KW, Chung SC, Sung JJ, To KF. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. *Clin Cancer Res* 2002; **8**: 1761-1766 [PMID: 12060614]

86 **Zheng Y**, Chen L, Li J, Yu B, Su L, Chen X, Yu Y, Yan M, Liu B, Zhu Z. Hypermethylated DNA as potential biomarkers for gastric cancer diagnosis. *Clin Biochem* 2011; **44**: 1405-1411 [PMID: 21945024 DOI: 10.1016/j.clinbiochem.2011.09.006]

87 **Chen L**, Su L, Li J, Zheng Y, Yu B, Yu Y, Yan M, Gu Q, Zhu Z, Liu B. Hypermethylated FAM5C and MYLK in serum as diagnosis and pre-warning markers for gastric cancer. *Dis Markers* 2012; **32**: 195-202 [PMID: 22377736 DOI: 10.3233/DMA-2011-0877]

88 Ling ZQ, Lv P, Lu XX, Yu JL, Han J, Ying LS, Zhu X, Zhu WY, Fang XH, Wang S, Wu YC. Circulating Methylated XAF1 DNA Indicates Poor Prognosis for Gastric Cancer. *PLoS One* 2013; **8**: e67195 [PMID: 23826230 DOI: 10.1371/journal.pone.0067195]

89 **Gevensleben H**, Garcia-Murillas I, Graeser MK, Schiavon G, Osin P, Parton M, Smith IE, Ashworth A, Turner NC. Noninvasive detection of HER2 amplification with plasma DNA digital PCR. *Clin Cancer Res* 2013; **19**: 3276-3284 [PMID: 23637122 DOI: 10.1158/1078-0432.CCR-12-3768]

90 **Diehl F**, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Diaz LA. Circulating mutant DNA to assess tumor dynamics. *Nat Med* 2008; **14**: 985-990 [PMID: 18670422 DOI: 10.1038/nm.1789]

91 **Park KU**, Lee HE, Park do J, Jung EJ, Song J, Kim HH, Choe G, Kim WH, Lee HS. MYC quantitation in cell-free plasma DNA by real-time PCR for gastric cancer diagnosis. *Clin Chem Lab Med* 2009; **47**: 530-536 [PMID: 19302034 DOI: 10.1515/CCLM.2009.126]

92 **Lee HE**, Park KU, Yoo SB, Nam SK, Park do J, Kim HH, Lee HS. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. *Eur J Cancer* 2013; **49**: 1448-1457 [PMID: 23146959 DOI: 10.1016/j.ejca.2012.10.018]

93 **Reddi KK**, Holland JF. Elevated serum ribonuclease in patients with pancreatic cancer. *Proc Natl Acad Sci U S A* 1976; **73**: 2308-2310 [PMID: 1065880]

94 **Maor D**, Mardiney MR, Jr. Alteration of human serum ribonuclease activity in malignancy. *CRC Crit Rev Clin Lab Sci* 1978; **10**: 89-111 [PMID: 752446]

95 **Wieczorek AJ**, Sitaramam V, Machleidt W, Rhyner K, Perruchoud AP, Block LH. Diagnostic and prognostic value of RNA-proteolipid in sera of patients with malignant disorders following therapy: first clinical evaluation of a novel tumor marker. *Cancer Res* 1987; **47**: 6407-6412 [PMID: 2445471]

96 **Wieczorek AJ**, Rhyner C, Block LH. Isolation and characterization of an RNA-proteolipid complex associated with the malignant state in humans. *Proc Natl Acad Sci U S A* 1985; **82**: 3455-3459 [PMID: 2582412]

97 **Kopreski MS**, Benko FA, Kwak LW, Gocke CD. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. *Clin Cancer Res* 1999; **5**: 1961-1965 [PMID: 10473072]

98 **Lo KW**, Lo YM, Leung SF, Tsang YS, Chan LY, Johnson PJ, Hjelm NM, Lee JC, Huang DP. Analysis of cell-free Epstein-Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma. *Clin Chem* 1999; **45**: 1292-1294 [PMID: 10430801]

99 **Dasí F**, Martínez-Rodes P, March JA, Santamaría J, Martínez-Javaloyas JM, Gil M, Aliño SF. Real-time quantification of human telomerase reverse transcriptase mRNA in the plasma of patients with prostate cancer. *Ann N Y Acad Sci* 2006; **1075**: 204-210 [PMID: 17108213 DOI: 10.1196/annals.1368.028]

100 **Chen XQ**, Bonnefoi H, Pelte MF, Lyautey J, Lederrey C, Movarekhi S, Schaeffer P, Mulcahy HE, Meyer P, Stroun M, Anker P. Telomerase RNA as a detection marker in the serum of breast cancer patients. *Clin Cancer Res* 2000; **6**: 3823-3826 [PMID: 11051224]

101 **Silva JM**, Rodriguez R, Garcia JM, Muñoz C, Silva J, Dominguez G, Provencio M, España P, Bonilla F. Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. *Gut* 2002; **50**: 530-534 [PMID: 11889075]

102 **Houseley J**, LaCava J, Tollervey D. RNA-quality control by the exosome. *Nat Rev Mol Cell Biol* 2006; **7**: 529-539 [PMID: 16829983 DOI: 10.1038/nrm1964]

103 **Simpson RJ**, Jensen SS, Lim JW. Proteomic profiling of exosomes: current perspectives. *Proteomics* 2008; **8**: 4083-4099 [PMID: 18780348 DOI: 10.1002/pmic.200800109]

104 **Lee RC**, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. *Cell* 1993; **75**: 843-854 [PMID: 8252621]

105 **Reinhart BJ**, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR, Ruvkun G. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. *Nature* 2000; **403**: 901-906 [PMID: 10706289 DOI: 10.1038/35002607]

106 **Pasquinelli AE**, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball EE, Degnan B, Müller P, Spring J, Srinivasan A, Fishman M, Finnerty J, Corbo J, Levine M, Leahy P, Davidson E, Ruvkun G. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. *Nature* 2000; **408**: 86-89 [PMID: 11081512 DOI: 10.1038/35040556]

107 **Ghildiyal M**, Zamore PD. Small silencing RNAs: an expanding universe. *Nat Rev Genet* 2009; **10**: 94-108 [PMID: 19148191 DOI: 10.1038/nrg2504]

108 **Lewis BP**, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. *Cell* 2003; **115**: 787-798 [PMID: 14697198]

109 **Rajewsky N**. microRNA target predictions in animals. *Nat Genet* 2006; **38** Suppl: S8-13 [PMID: 16736023 DOI: 10.1038/ng1798]

110 **Li C**, Feng Y, Coukos G, Zhang L. Therapeutic microRNA strategies in human cancer. *AAPS J* 2009; **11**: 747-757 [PMID: 19876744 DOI: 10.1208/s12248-009-9145-9]

111 **Trang P**, Weidhaas JB, Slack FJ. MicroRNAs as potential cancer therapeutics. *Oncogene* 2008; **27** Suppl 2: S52-S57 [PMID: 19956180 DOI: 10.1038/onc.2009.353]

112 **Mitchell PS**, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. *Proc Natl Acad Sci U S A* 2008; **105**: 10513-10518 [PMID: 18663219 DOI: 10.1073/pnas.0804549105]

113 **Chen X**, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. *Cell Res* 2008; **18**: 997-1006 [PMID: 18766170 DOI: 10.1038/cr.2008.282]

114 **Lawrie CH**, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Harris AL. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. *Br J Haematol* 2008; **141**: 672-675 [PMID: 18318758 DOI: 10.1111/j.1365-2141.2008.07077.x]

115 **Wong TS**, Liu XB, Wong BY, Ng RW, Yuen AP, Wei WI. Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue. *Clin Cancer Res* 2008; **14**: 2588-2592 [PMID: 18451220 DOI: 10.1158/1078-0432.CCR-07-0666]

116 **Zhang Y**, Liu D, Chen X, Li J, Li L, Bian Z, Sun F, Lu J, Yin Y, Cai X, Sun Q, Wang K, Ba Y, Wang Q, Wang D, Yang J, Liu P, Xu T, Yan Q, Zhang J, Zen K, Zhang CY. Secreted monocytic miR-150 enhances targeted endothelial cell migration. *Mol Cell* 2010; **39**: 133-144 [PMID: 20603081 DOI: 10.1016/j.molcel.2010.06.010]

117 **Arroyo JD**, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, Tait JF, Tewari M. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. *Proc Natl Acad Sci U S A* 2011; **108**: 5003-5008 [PMID: 21383194 DOI: 10.1073/pnas.1019055108]

118 **Vickers KC**, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. *Nat Cell Biol* 2011; **13**: 423-433 [PMID: 21423178 DOI: 10.1038/ncb2210]

119 **Turchinovich A**, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. *Nucleic Acids Res* 2011; **39**: 7223-7233 [PMID: 21609964 DOI: 10.1093/nar/gkr254]

120 **Zernecke A**, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, Hristov M, Köppel T, Jahantigh MN, Lutgens E, Wang S, Olson EN, Schober A, Weber C. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. *Sci Signal* 2009; **2**: ra81 [PMID: 19996457 DOI: 10.1126/scisignal.2000610]

121 **Ichikawa D**, Komatsu S, Konishi H, Otsuji E. Circulating microRNA in digestive tract cancers. *Gastroenterology* 2012; **142**: 1074-1078.e1 [PMID: 22433392 DOI: 10.1053/j.gastro.2012.03.008]

122 **Reid G**, Kirschner MB, van Zandwijk N. Circulating microRNAs: Association with disease and potential use as biomarkers. *Crit Rev Oncol Hematol* 2011; **80**: 193-208 [PMID: 21145252 DOI: 10.1016/j.critrevonc.2010.11.004]

123 **Kang Y**, Zhang J, Sun P, Shang J. Circulating cell-free human telomerase reverse transcriptase mRNA in plasma and its potential diagnostic and prognostic value for gastric cancer. *Int J Clin Oncol* 2013; **18**: 478-486 [PMID: 22527847 DOI: 10.1007/s10147-012-0405-9]

124 **Tsujiura M**, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, Konishi H, Morimura R, Deguchi K, Fujiwara H, Okamoto K, Otsuji E. Circulating microRNAs in plasma of patients with gastric cancers. *Br J Cancer* 2010; **102**: 1174-1179 [PMID: 20234369 DOI: 10.1038/sj.bjc.6605608]

125 **Konishi H**, Ichikawa D, Komatsu S, Shiozaki A, Tsujiura M, Takeshita H, Morimura R, Nagata H, Arita T, Kawaguchi T, Hirashima S, Fujiwara H, Okamoto K, Otsuji E. Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma. *Br J Cancer* 2012; **106**: 740-747 [PMID: 22262318 DOI: 10.1038/bjc.2011.588]

126 **Bartel DP**. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 2004; **116**: 281-297 [PMID: 14744438]

127 **Ambros V**. The functions of animal microRNAs. *Nature* 2004; **431**: 350-355 [PMID: 15372042 DOI: 10.1038/nature02871]

128 **Arita T**, Ichikawa D, Konishi H, Komatsu S, Shiozaki A, Shoda K, Kawaguchi T, Hirajima S, Nagata H, Kubota T, Fujiwara H, Okamoto K, Otsuji E. Circulating long non-coding RNAs in plasma of patients with gastric cancer. *Anticancer Res* 2013; **33**: 3185-3193 [PMID: 23898077 DOI: 33/8/3185]

129 **Ørom UA**, Derrien T, Beringer M, Gumireddy K, Gardini A, Bussotti G, Lai F, Zytnicki M, Notredame C, Huang Q, Guigo R, Shiekhattar R. Long noncoding RNAs with enhancer-like function in human cells. *Cell* 2010; **143**: 46-58 [PMID: 20887892 DOI: 10.1016/j.cell.2010.09.001]

130 **Mercer TR**, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. *Nat Rev Genet* 2009; **10**: 155-159 [PMID: 19188922 DOI: 10.1038/nrg2521]

131 **Yang F**, Bi J, Xue X, Zheng L, Zhi K, Hua J, Fang G. Up-regulated long non-coding RNA H19 contributes to proliferation of gastric cancer cells. *FEBS J* 2012; **279**: 3159-3165 [PMID: 22776265 DOI: 10.1111/j.1742-4658.2012.08694.x]

132 **Yang F**, Xue X, Bi J, Zheng L, Zhi K, Gu Y, Fang G. Long noncoding RNA CCAT1, which could be activated by c-Myc, promotes the progression of gastric carcinoma. *J Cancer Res Clin Oncol* 2013; **139**: 437-445 [PMID: 23143645 DOI: 10.1007/s00432-012-1324-x]

133 **Funaki NO**, Tanaka J, Kasamatsu T, Ohshio G, Hosotani R, Okino T, Imamura M. Identification of carcinoembryonic antigen mRNA in circulating peripheral blood of pancreatic carcinoma and gastric carcinoma patients. *Life Sci* 1996; **59**: 2187-2199 [PMID: 8950323]

134 **Mori M**, Mimori K, Ueo H, Karimine N, Barnard GF, Sugimachi K, Akiyoshi T. Molecular detection of circulating solid carcinoma cells in the peripheral blood: the concept of early systemic disease. *Int J Cancer* 1996; **68**: 739-743 [PMID: 8980176]

135 **Aihara T**, Noguchi S, Ishikawa O, Furukawa H, Hiratsuka M, Ohigashi H, Nakamori S, Monden M, Imaoka S. Detection of pancreatic and gastric cancer cells in peripheral and portal blood by amplification of keratin 19 mRNA with reverse transcriptase-polymerase chain reaction. *Int J Cancer* 1997; **72**: 408-411 [PMID: 9247282]

136 **Soeth E**, Vogel I, Röder C, Juhl H, Marxsen J, Krüger U, Henne-Bruns D, Kremer B, Kalthoff H. Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR. *Cancer Res* 1997; **57**: 3106-3110 [PMID: 9242433]

137 **Yeh KH**, Chen YC, Yeh SH, Chen CP, Lin JT, Cheng AL. Detection of circulating cancer cells by nested reverse transcription-polymerase chain reaction of cytokeratin-19 (K19)--possible clinical significance in advanced gastric cancer. *Anticancer Res* 1998; **18**: 1283-1286 [PMID: 9615802]

138 **Noh YH**, Im G, Ku JH, Lee YS, Ahn MJ. Detection of tumor cell contamination in peripheral blood by RT-PCR in gastrointestinal cancer patients. *J Korean Med Sci* 1999; **14**: 623-628 [PMID: 10642939]

139 **Majima T**, Ichikura T, Takayama E, Chochi K, Mochizuki H. Detecting circulating cancer cells using reverse transcriptase-polymerase chain reaction for cytokeratin mRNA in peripheral blood from patients with gastric cancer. *Jpn J Clin Oncol* 2000; **30**: 499-503 [PMID: 11155920]

140 **Noh YH**, Kim JA, Lim GR, Ro YT, Koo JH, Lee YS, Han DS, Park HK, Ahn MJ. Detection of circulating tumor cells in patients with gastrointestinal tract cancer using RT-PCR and its clinical implications. *Exp Mol Med* 2001; **33**: 8-14 [PMID: 11322488 DOI: 10.1038/emm.2001.2]

141 **Sumikura S**, Ishigami S, Natsugoe S, Miyazono F, Tokuda K, Nakajo A, Okumura H, Matsumoto M, Hokita S, Aikou T. Disseminated cancer cells in the blood and expression of sialylated antigen in gastric cancer. *Cancer Lett* 2003; **200**: 77-83 [PMID: 14550955]

142 **Koike H**, Ichikawa D, Ikoma H, Otsuji E, Kitamura K, Yamagishi H. Comparison of methylation-specific polymerase chain reaction (MSP) with reverse transcriptase-polymerase chain reaction (RT-PCR) in peripheral blood of gastric cancer patients. *J Surg Oncol* 2004; **87**: 182-186 [PMID: 15334633 DOI: 10.1002/jso.20106]

143 **Friederichs J**, Gertler R, Rosenberg R, Nahrig J, Führer K, Holzmann B, Dittler HJ, Dahm M, Thorban S, Nekarda H, Siewert JR. Prognostic impact of CK-20-positive cells in peripheral venous blood of patients with gastrointestinal carcinoma. *World J Surg* 2005; **29**: 422-428 [PMID: 15770378 DOI: 10.1007/s00268-004-7662-3]

144 **Illert B**, Fein M, Otto C, Cording F, Stehle D, Thiede A, Timmermann W. Disseminated tumor cells in the blood of patients with gastric cancer are an independent predictive marker of poor prognosis. *Scand J Gastroenterol* 2005; **40**: 843-849 [PMID: 16109661 DOI: 10.1080/00365520510015557]

145 **Seo JH**, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS, Lee SW, Choi JH, Park YT, Mok YJ, Kim CS, Kim JS. Follow-up study of peripheral blood carcinoembryonic antigen mRNA using reverse transcription-polymerase chain reaction as an early marker of clinical recurrence in patients with curatively resected gastric cancer. *Am J Clin Oncol* 2005; **28**: 24-29 [PMID: 15685031]

146 **Kolodziejczyk P**, Pituch-Noworolska A, Drabik G, Kulig J, Szczepanik A, Sierzega M, Gurda A, Popiela T, Zembala M. The effects of preoperative chemotherapy on isolated tumour cells in the blood and bone marrow of gastric cancer patients. *Br J Cancer* 2007; **97**: 589-592 [PMID: 17700573 DOI: 10.1038/sj.bjc.6603904]

147 **Tani N**, Ichikawa D, Ikoma D, Tomita H, Sai S, Ikoma H, Okamoto K, Ochiai T, Ueda Y, Otsuji E, Yamagishi H, Miura N, Shiota G. Circulating cell-free mRNA in plasma as a tumor marker for patients with primary and recurrent gastric cancer. *Anticancer Res* 2007; **27**: 1207-1212 [PMID: 17465264]

148 **Koga T**, Tokunaga E, Sumiyoshi Y, Oki E, Oda S, Takahashi I, Kakeji Y, Baba H, Maehara Y. Detection of circulating gastric cancer cells in peripheral blood using real time quantitative RT-PCR. *Hepatogastroenterology* 2008; **55**: 1131-1135 [PMID: 18705345]

149 **Yie SM**, Lou B, Ye SR, Cao M, He X, Li P, Hu K, Rao L, Wu SM, Xiao HB, Gao E. Detection of survivin-expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse. *Ann Surg Oncol* 2008; **15**: 3073-3082 [PMID: 18670822 DOI: 10.1245/s10434-008-0069-x]

150 **Bertazza L**, Mocellin S, Marchet A, Pilati P, Gabrieli J, Scalerta R, Nitti D. Survivin gene levels in the peripheral blood of patients with gastric cancer independently predict survival. *J Transl Med* 2009; **7**: 111 [PMID: 20028510 DOI: 10.1186/1479-5876-7-111]

151 **Kita Y**, Fukagawa T, Mimori K, Kosaka Y, Ishikawa K, Aikou T, Natsugoe S, Sasako M, Mori M. Expression of uPAR mRNA in peripheral blood is a favourite marker for metastasis in gastric cancer cases. *Br J Cancer* 2009; **100**: 153-159 [PMID: 19050704 DOI: 10.1038/sj.bjc.6604806]

152 **Qiu MZ**, Li ZH, Zhou ZW, Li YH, Wang ZQ, Wang FH, Huang P, Aziz F, Wang DY, Xu RH. Detection of carcinoembryonic antigen messenger RNA in blood using quantitative real-time reverse transcriptase-polymerase chain reaction to predict recurrence of gastric adenocarcinoma. *J Transl Med* 2010; **8**: 107 [PMID: 21040522 DOI: 10.1186/1479-5876-8-107]

153 **Saad AA**, Awed NM, Abd Elkerim NN, El-Shennawy D, Alfons MA, Elserafy ME, Darwish YW, Barakat EM, Ezz-Elarab SS. Prognostic significance of E-cadherin expression and peripheral blood micrometastasis in gastric carcinoma patients. *Ann Surg Oncol* 2010; **17**: 3059-3067 [PMID: 20563657 DOI: 10.1245/s10434-010-1151-8]

154 **Arigami T**, Uenosono Y, Hirata M, Yanagita S, Ishigami S, Natsugoe S. B7-H3 expression in gastric cancer: a novel molecular blood marker for detecting circulating tumor cells. *Cancer Sci* 2011; **102**: 1019-1024 [PMID: 21251161 DOI: 10.1111/j.1349-7006.2011.01877.x]

155 **Cao W**, Yang W, Li H, Lou G, Jiang J, Geng M, Xi W, Ren R, Qu Q, Jin X, Zhu Y, Jin Y. Using detection of survivin-expressing circulating tumor cells in peripheral blood to predict tumor recurrence following curative resection of gastric cancer. *J Surg Oncol* 2011; **103**: 110-115 [PMID: 21259243 DOI: 10.1002/jso.21777]

156 **Dardaei L**, Shahsavani R, Ghavamzadeh A, Behmanesh M, Aslankoohi E, Alimoghaddam K, Ghaffari SH. The detection of disseminated tumor cells in bone marrow and peripheral blood of gastric cancer patients by multimarker (CEA, CK20, TFF1 and MUC2) quantitative real-time PCR. *Clin Biochem* 2011; **44**: 325-330 [PMID: 21130081 DOI: 10.1016/j.clinbiochem.2010.11.005]

157 **Ren J**, Chen Z, Juan SJ, Yong XY, Pan BR, Fan DM. Detection of circulating gastric carcinoma-associated antigen MG7-Ag in human sera using an established single determinant immuno-polymerase chain reaction technique. *Cancer* 2000; **88**: 280-285 [PMID: 10640958]

158 **Lo YM**, Chan WY, Ng EK, Chan LY, Lai PB, Tam JS, Chung SC. Circulating Epstein-Barr virus DNA in the serum of patients with gastric carcinoma. *Clin Cancer Res* 2001; **7**: 1856-1859 [PMID: 11448896]

159 **Kanyama Y**, Hibi K, Nakayama H, Kodera Y, Ito K, Akiyama S, Nakao A. Detection of p16 promoter hypermethylation in serum of gastric cancer patients. *Cancer Sci* 2003; **94**: 418-420 [PMID: 12824886]

160 **Ichikawa D**, Koike H, Ikoma H, Ikoma D, Tani N, Otsuji E, Kitamura K, Yamagishi H. Detection of aberrant methylation as a tumor marker in serum of patients with gastric cancer. *Anticancer Res* 2004; **24**: 2477-2481 [PMID: 15330201]

161 **Koike H**, Ichikawa D, Ikoma H, Tani N, Ikoma D, Otsuji E, Okamoto K, Ueda Y, Kitamura K, Yamagishi H. Comparison of serum aberrant methylation and conventional tumor markers in gastric cancer patients. *Hepatogastroenterology* 2005; **52**: 1293-1296 [PMID: 16001680]

162 **Leung WK**, To KF, Chu ES, Chan MW, Bai AH, Ng EK, Chan FK, Sung JJ. Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer. *Br J Cancer* 2005; **92**: 2190-2194 [PMID: 15942635 DOI: 10.1038/sj.bjc.6602636]

163 **Ikoma H**, Ichikawa D, Daito I, Nobuyuki T, Koike H, Okamoto K, Ochiai T, Ueda Y, Yamagishi H, Otsuji E. Clinical application of methylation specific-polymerase chain reaction in serum of patients with gastric cancer. *Hepatogastroenterology* 2007; **54**: 946-950 [PMID: 17591100]

164 **Tan SH**, Ida H, Lau QC, Goh BC, Chieng WS, Loh M, Ito Y. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. *Oncol Rep* 2007; **18**: 1225-1230 [PMID: 17914577]

165 **Abbaszadegan MR**, Moaven O, Sima HR, Ghafarzadegan K, A'rabi A, Forghani MN, Raziee HR, Mashhadinejad A, Jafarzadeh M, Esmaili-Shandiz E, Dadkhah E. p16 promoter hypermethylation: a useful serum marker for early detection of gastric cancer. *World J Gastroenterol* 2008; **14**: 2055-2060 [PMID: 18395906]

166 **Kolesnikova EV**, Tamkovich SN, Bryzgunova OE, Shelestyuk PI, Permyakova VI, Vlassov VV, Tuzikov AS, Laktionov PP, Rykova EY. Circulating DNA in the blood of gastric cancer patients. *Ann N Y Acad Sci* 2008; **1137**: 226-231 [PMID: 18837952 DOI: 10.1196/annals.1448.009]

167 **Wang YC**, Yu ZH, Liu C, Xu LZ, Yu W, Lu J, Zhu RM, Li GL, Xia XY, Wei XW, Ji HZ, Lu H, Gao Y, Gao WM, Chen LB. Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. *World J Gastroenterol* 2008; **14**: 3074-3080 [PMID: 18494062]

168 **Chen Z**, Fan JQ, Li J, Li QS, Yan Z, Jia XK, Liu WD, Wei LJ, Zhang FZ, Gao H, Xu JP, Dong XM, Dai J, Zhou HM. Promoter hypermethylation correlates with the Hsulf-1 silencing in human breast and gastric cancer. *Int J Cancer* 2009; **124**: 739-744 [PMID: 19006069 DOI: 10.1002/ijc.23960]

169 **Sakakura C**, Hamada T, Miyagawa K, Nishio M, Miyashita A, Nagata H, Ida H, Yazumi S, Otsuji E, Chiba T, Ito K, Ito Y. Quantitative analysis of tumor-derived methylated RUNX3 sequences in the serum of gastric cancer patients. *Anticancer Res* 2009; **29**: 2619-2625 [PMID: 19596937 DOI: 29/7/2619]

170 **Zhang Y**, Ye X, Geng J, Chen L. Epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in gastric and colorectal adenocarcinoma. *Hepatogastroenterology* 2010; **57**: 1614-1619 [PMID: 21443130]

171 **Hibi K**, Goto T, Shirahata A, Saito M, Kigawa G, Nemoto H, Sanada Y. Detection of TFPI2 methylation in the serum of gastric cancer patients. *Anticancer Res* 2011; **31**: 3835-3838 [PMID: 22110206]

172 **Ng EK**, Leung CP, Shin VY, Wong CL, Ma ES, Jin HC, Chu KM, Kwong A. Quantitative analysis and diagnostic significance of methylated SLC19A3 DNA in the plasma of breast and gastric cancer patients. *PLoS One* 2011; **6**: e22233 [PMID: 21789241 DOI: 10.1371/journal.pone.0022233]

173 **Raja UM**, Gopal G, Rajkumar T. Intragenic DNA methylation concomitant with repression of ATP4B and ATP4A gene expression in gastric cancer is a potential serum biomarker. *Asian Pac J Cancer Prev* 2012; **13**: 5563-5568 [PMID: 23317218]

174 **Shirahata A**, Sakuraba K, Kitamura Y, Yokomizo K, Gotou T, Saitou M, Kigawa G, Nemoto H, Sanada Y, Hibi K. Detection of vimentin methylation in the serum of patients with gastric cancer. *Anticancer Res* 2012; **32**: 791-794 [PMID: 22399595]

175 **Balgkouranidou I**, Karayiannakis A, Matthaios D, Bolanaki H, Tripsianis G, Tentes AA, Lianidou E, Chatzaki E, Fiska A, Lambropoulou M, Kolios G, Kakolyris S. Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival. *Clin Chem Lab Med* 2013; **51**: 1505-1510 [PMID: 23403728 DOI: 10.1515/cclm-2012-0320]

176 **Xu W**, Zhou H, Qian H, Bu X, Chen D, Gu H, Zhu W, Yan Y, Mao F. Combination of circulating CXCR4 and Bmi-1 mRNA in plasma: A potential novel tumor marker for gastric cancer. *Mol Med Rep* 2009; **2**: 765-771 [PMID: 21475899 DOI: 10.3892/mmr\_00000170]

177 **Liu R**, Zhang C, Hu Z, Li G, Wang C, Yang C, Huang D, Chen X, Zhang H, Zhuang R, Deng T, Liu H, Yin J, Wang S, Zen K, Ba Y, Zhang CY. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. *Eur J Cancer* 2011; **47**: 784-791 [PMID: 21112772 DOI: 10.1016/j.ejca.2010.10.025]

178 **Liu H**, Zhu L, Liu B, Yang L, Meng X, Zhang W, Ma Y, Xiao H. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. *Cancer Lett* 2012; **316**: 196-203 [PMID: 22169097 DOI: 10.1016/j.canlet.2011.10.034]

179 **Song MY**, Pan KF, Su HJ, Zhang L, Ma JL, Li JY, Yuasa Y, Kang D, Kim YS, You WC. Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer. *PLoS One* 2012; **7**: e33608 [PMID: 22432036 DOI: 10.1371/journal.pone.0033608]

180 **Tsai KW**, Liao YL, Wu CW, Hu LY, Li SC, Chan WC, Ho MR, Lai CH, Kao HW, Fang WL, Huang KH, Lin WC. Aberrant expression of miR-196a in gastric cancers and correlation with recurrence. *Genes Chromosomes Cancer* 2012; **51**: 394-401 [PMID: 22420029]

181 **Wang B**, Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. *J Cancer Res Clin Oncol* 2012; **138**: 1659-1666 [PMID: 22638884 DOI: 10.1007/s00432-012-1244-9]

182 **Wang M**, Gu H, Wang S, Qian H, Zhu W, Zhang L, Zhao C, Tao Y, Xu W. Circulating miR-17-5p and miR-20a: molecular markers for gastric cancer. *Mol Med Rep* 2012; **5**: 1514-1520 [PMID: 22406928 DOI: 10.3892/mmr.2012.828]

183 **Zhang WH**, Gui JH, Wang CZ, Chang Q, Xu SP, Cai CH, Li YN, Tian YP, Yan L, Wu B. The identification of miR-375 as a potential biomarker in distal gastric adenocarcinoma. *Oncol Res* 2012; **20**: 139-147 [PMID: 23461060]

184 **Gorur A**, Balci Fidanci S, Dogruer Unal N, Ayaz L, Akbayir S, Yildirim Yaroglu H, Dirlik M, Serin MS, Tamer L. Determination of plasma microRNA for early detection of gastric cancer. *Mol Biol Rep* 2013; **40**: 2091-2096 [PMID: 23212612 DOI: 10.1007/s11033-012-2267-7]

185 **Kim SY**, Jeon TY, Choi CI, Kim DH, Kim DH, Kim GH, Ryu DY, Lee BE, Kim HH. Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer. *J Mol Diagn* 2013; **15**: 661-669 [PMID: 23806809 DOI: 10.1016/j.jmoldx.2013.04.004]

186 **Komatsu S**, Ichikawa D, Tsujiura M, Konishi H, Takeshita H, Nagata H, Kawaguchi T, Hirajima S, Arita T, Shiozaki A, Kubota T, Fujiwara H, Okamoto K, Otsuji E. Prognostic impact of circulating miR-21 in the plasma of patients with gastric carcinoma. *Anticancer Res* 2013; **33**: 271-276 [PMID: 23267156]

187 **Li C**, Li JF, Cai Q, Qiu QQ, Yan M, Liu BY, Zhu ZG. MiRNA-199a-3p: A potential circulating diagnostic biomarker for early gastric cancer. *J Surg Oncol* 2013; **108**: 89-92 [PMID: 23733518 DOI: 10.1002/jso.23358]

**P-Reviewers:** Streba CT, Zhu YL **S-Editor:** Gou SX  **L-Editor: E-Editor:**



**Figure 1 Flow chart of current and potential applications of circulating tumor cell and circulating cell-free nucleic acids technologies.** Circulating tumor cells (CTCs): The blood samples from cancer patients are processed through various isolation/enrichment and detection techniques. A new *in vivo* approach allows the enrichment of CTCs directly from a peripheral vein of patients, using a wire functionalized by attachment of epithelial cell adhesion antibodies[[32](#_ENREF_32)]. CTCs are usually captured along with contaminating leukocytes. Various detection methods are utilized to detect the rare cell population in the bloodstream. Circulating cell-free nucleic acids (cfNAs): Plasma/serum are generally isolated with centrifuge techniques and subsequently processed for the extraction of specific nucleic acids. Cancer-specific alterations are most commonly analyzed in circulating DNA. Circulating miRNA has attracted increasing attention because of its stability in plasma/serum. Most recently, long non-coding RNA in plasma was also evaluated as a potent biomarker in gastric cancer patients. CGH: Comparative genome hybridization; FACS: Fluorescence activated cell sorter; FISH: Fluorescence *in situ* hybridization; FAST: Fiberoptic array scanning technology; EPISPOT: Epithelial immunospot; qRT-PCR: Quantitative real-time polymerase chain reaction; LOH: Loss of heterozygosity.

**Table 1 Detection of circulating tumor cells in gastric cancer**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristic and number of patients** | **Control (*n*)** | **Detection method** | **Detection rate/statistic value** | **Author** |
| Pre or post treatment | 9 (PB) | 4 | RT-PCR | CEA mRNA | 22.2% | (Pt.) | Funaki *et al*[[133](#_ENREF_133)] |
|  |  |  |  | 0% | (Ctrl.) |  |
| I-IV | 20 (PB) | 22 | RT-PCR | CEA mRNA | 35% | (Pt.) | Mori *et al*[[134](#_ENREF_134)] |
|  |  |  |  |  | 0% | (Ctrl.) |  |
| I-IV | 49 (PB) | 50 | RT-PCR | CK19 mRNA | 0% | (PB) | Aihara *et al*[[135](#_ENREF_135)] |
|  | 21 (PV) |  |  |  | 0% | (PV) |  |
|  |  |  |  |  | 0% | (Ctrl.) |  |
| I-IV | 30 (PB) | 58 | RT-PCR | CK20 mRNA | 16.7% | (Pt.) | Soeth [[136](#_ENREF_136)] |
|  |  |  |  |  | 3.4% | (Ctrl.) |  |
| Inoperable/metastatic | 34 (PB) | 33 | RT-PCR | CK19 mRNA | 20.6% | (Pt.) | Yeh [[137](#_ENREF_137)] |
|  |  |  |  | 0% | (Ctrl.) |  |
| I,III,IV | 35 (PB) | 9 | RT-PCR | CEA mRNA | 45.7% | (Pt.) | Noh [[138](#_ENREF_138)] |
|  |  |  |  |  | 9 0% | (Ctrl.) |  |
| I-IV | 52 (PB) | 14 | RT-PCR | CK19 mRNA | 9.6% | (Pt.) | Majima [[139](#_ENREF_139)] |
|  |  |  |  |  | 0% | (Ctrl.) |  |
|  |  |  |  | CK20 mRNA | 9.6% | (Pt.) |  |
|  |  |  |  |  | 1% | (Ctrl.) |  |
| I-IV | 41 (PB) |  | RT-PCR | CEA mRNA | 22.2% | (before curative surgery) | Nishida [[60](#_ENREF_60)] |
| (36 with curative surgery) |  |  |  | 33.3% | (during curative surgery) |  |
| (5 with inoperable) |  |  |  | 80% | (inoperable Pt.) |  |
| I-IV | 57 (PA) | 30 | RT-PCR | CEA mRNA | PA: 17.5% |  | Miyazono [[59](#_ENREF_59)] |
|  | 49 (PV) |  |  |  | PV: 18.4% |  |  |
|  | 51 (SVC) |  |  |  | SVC: 1 21.6% |  |
|  |  |  |  |  | 8.8% | (before surgery) | At least either one positive in PA/PV/SVC |
|  |  |  |  |  | 33.3% | (during surgery) |
|  |  |  |  |  | 0% | (Ctrl.) |
| EGC, III | 29 (PB) | 15 | RT-PCR | CEA mRNA | EGC: 22.2% | (after surgery) | Noh [[140](#_ENREF_140)] |
| (paired, after surgery during surgery and follow-up) |  |  |  | IIIa: 20% |  |  |
|  |  |  | IIIb: 26.7% |  |  |
|  |  |  |  |  | Total: 24.1% |  |
|  |  |  |  |  | EGC: 22.2% | (during follow-up) |  |
|  |  |  |  |  | IIIa: 20% |  |  |
|  |  |  |  |  | IIIb: 34.4% |  |  |
|  |  |  |  |  | Total: 34.4% |  |
|  |  |  |  |  | 0% | (Ctrl.) |  |
| I-IV | 106 (PB) |  | RT-PCR | CEA mRNA | 40.6% |  | Sumikura [[141](#_ENREF_141)] |
| (during surgery) |  |  |  |  |  | (2003) |
| I-IV | 41 (PB) | 10 | RT-PCR | CEA mRNA | 24.4% | (Pt.) | Koike [[142](#_ENREF_142)] |
|  |  |  |  |  | 0% | (Ctrl.) | (2004) |
| I-IV | 46 (PB) | 10 (with benign GI disease) | qRT-PCR | CK20 mRNA | 27.8% | (Pt. with EGJ cancer) | Friederichs [[143](#_ENREF_143)] |
|  | (18 EGJ caner) | 100 (tumor-free Ctrl.) | Oncoquick densitygradient centrifugation | 21.4% | (Pt. with GC) | (2005) |
|  | (28 with GC) |  |  |  | 0% | (with benign GI disease) |  |
|  |  |  |  |  | 1% | (tumor-free Ctrl.) |  |
| I-IV | 59 (PB) | 15 | qRT-PCR | CEA mRNA | 0% | (before surgery) | Ikeguchi [[58](#_ENREF_58)] |
|  |  |  |  |  | 45.8% | (after surgery) | (2005) |
|  |  |  |  |  | 0% | (Ctrl.) |  |
| I-IV | 70 (PB) |  | RT-PCR | CK20 mRNA | 36.6% | (Pt. with curative resection) | Illert [[144](#_ENREF_144)] |
| (41 with curative resection) |  |  |  | 44.8% | (Pt. with residual tumor) | (2005) |
| (29 with residual tumor) |  |  |  | Total: 40% |  |
| I-III | 46 (PB) | 13 | RT-PCR | CEA mRNA | 52.2% | (before surgery) | Seo [[145](#_ENREF_145)] |
| (with curative resection) |  |  |  | 19.6% | (after surgery) | (2005) |
| (paired, before and after surgery) |  |  |  | 0% | (Ctrl.) |  |
| I-IV | 52 (PB) | 36 | RT-PCR | c-Met mRNA | 61.5% | (Pt.) | Uen [[42](#_ENREF_42)] |
|  |  |  |  |  | 5.6% | (Ctrl.) | (2006) |
|  |  |  |  | MUC1 mRNA | 71.2% | (Pt.) |  |
|  |  |  |  |  | 8.3% | (Ctrl.) |  |
| I-IV | 42 (PB) | 30 | RT-PCR | hTERT mRNA | 61.9% | (Pt.) | Wu [[43](#_ENREF_43)] |
|  |  |  |  |  | 0% | (Ctrl.) | (2006) |
|  |  |  |  | CK19 mRNA | 69.0% | (Pt.) |  |
|  |  |  |  |  | 3.3% | (Ctrl.) |  |
|  |  |  |  | CK20 mRNA | 61.9% | (Pt.) |  |
|  |  |  |  |  | 3.3% | (Ctrl.) |  |
|  |  |  |  | CEA mRNA | 78.6% | (Pt.) |  |
|  |  |  |  |  | 0% | (Ctrl.) |  |
| I-IV | 64 (PB) | 80 | MAH | hTERT mRNA | 81.3% |  | Wu [[44](#_ENREF_44)] |
|  |  |  |  | CK19 mRNA | 78.1% |  | (2006) |
|  |  |  |  | CK20 mRNA | 82.8% |  |  |
|  |  |  |  | MUC1 mRNA | 84.4% |  |  |
|  |  |  |  |  | No detection in controls |  |
| I-IV | 32 (PB) |  | FACS/ICC | CK8/18/19 | 21.9% | (before chemotherapy) | Kolodziejczyk [[146](#_ENREF_146)] |
| (paired, before and after chemotherapy) |  |  |  | 15.6% | (after chemotherapy) | (2007) |
| I-IV | 57 (PB)(before surgery) |  | FACS/ICC | CK8/18/19 | 54.4% | (before surgery) | Pituch-Noworolska [[61](#_ENREF_61)] |
|  | 52 (PB)(after surgery) |  |  |  | 21.2% | (after surgery) | (2007) |
|  | 56 (TDB) |  |  |  | 26.8% | (TDB sample) |  |
| I-IV | 52 (PB) | 20 | qRT-PCR | CEA mRNA | 5.0% | (before surgery) | Tani [[147](#_ENREF_147)] |
|  | (40 pre-ope) |  |  |  | 16.7% | (after surgery) | (2007) |
|  | (12 post-ope) |  |  |  |  |  |  |
| I-IV | 41 (PB) | 41 | Cell search system | EpCAM | 14.3% | (Nonmetastatic GC) | Hiraiwa [[55](#_ENREF_55)] |
|  |  |  |  | CK8/18/19 | 55.6% | (metastatic GC) | (2008) |
|  |  |  |  |  | 0% | (Ctrl.) |  |
| I-IV | 101 (PB) | 14 | qRT-PCR | CK19 mRNA↑ | *P* = 0.0127 | Curative resection (*n* = 69) *vs* Ctrl. (*n* = 14) | Koga [[148](#_ENREF_148)] |
| (69 with curative ope) |  |  |  | *P* = 0.0087 | Non-curative resection (*n* = 32) *vs* Ctrl. (*n* = 14) | (2008) |
| (32 with non-curative ope) |  |  | CK20 mRNA↑ | *P* = 0.0022 | Non-curative resection (*n* = 32) *vs* Ctrl. (*n* = 14) |  |
| I-IV | 810 (PB) | 29 | RT-PCR | MT1-MMP mRNA | 22.8% |  | Mimori [[57](#_ENREF_57)] |
|  |  |  |  |  | No data for Ctrl. |  | (2008) |
| I-IV | 55 (PB) | 86 | RT-PCR ELISA | Survivin mRNA↑ | 45.5% | (Pt.) | Yie [[149](#_ENREF_149)] |
|  |  |  |  |  | AUC = 0.772 | Pt. (*n* = 55) *vs* cCtrl. (*n* = 86) | (2008) |
|  I-IV | 70 (PB) | 20 | qRT-PCR | CEA mRNA | 45.7% |  | Bertazza [[150](#_ENREF_150)] |
|  |  |  |  | CK19 mRNA | 97.1% |  | (2009) |
|  |  |  |  | VEGF mRNA | 38.6% |  |  |
|  |  |  |  | Survivin mRNA | 98.6% |  |  |
|  |  |  |  |  | (Control samples were used the calibrator source.) |  |
| I-IV | 846 (PB) | 25 | qRT-PCR | uPAR mRNA↑ | 404/846 47.8% |  | Kita [[151](#_ENREF_151)] |
|  |  |  |  |  | *P* < 0.0001 | Pt. (*n* = 846) *vs* Ctrl. (*n* = 25) | (2009) |
| Advanced | 52 (PB) |  | Cell search system | EpCAM | 32.7% | (baseline) | Matsusaka [[56](#_ENREF_56)] |
| (paired, before and during chemotherapy) |  |  | CK8/18/19 | 13.7% | (2 wk after chemotherapy) | (2010) |
|  |  |  | 18.8% | (4 wk after chemotherapy) |  |
| I-IV | 123 (PB) | 30 | qRT-PCR | CEA mRNA | 36.6% | (Pt.) | Qiu [[152](#_ENREF_152)] |
|  |  |  |  |  | 30% | (Ctrl.) | (2010) |
| I-IV | 30 (PB) |  | qRT-PCR | CK18 mRNA | I/II: 81.8% |  | Saad [[153](#_ENREF_153)] |
| (after curative surgery) |  |  |  | III/IV: 6/19 31.6% | (2010) |
|  |  |  |  |  | Total: 50% |  |  |
| N/A | 90 (PB) |  |  | miR-106a↑ | *P* = 0.006 | Pre-ope *vs* Ctrl. | Zhou [[48](#_ENREF_48)] |
| (90 before surgery) |  |  |  | AUC = 0.684 |  | (2010) |
| (41 preoperative) |  |  |  | *P* = 0.016 | Post-ope *vs* Ctrl. |  |
| (49 postoperative) |  |  | miR-17↑ | *P* = 0.001 | Pre-ope *vs* Ctrl. |  |
|  |  |  |  |  | AUC = 0.743 |  |  |
|  |  |  |  |  | *P* = 0.019 | Post-ope *vs* Ctrl. |  |
| I-IV | 95 (PB) | 21 | qRT-PCR | B7-H3 mRNA↑ | 50.5% |  | Arigami [[154](#_ENREF_154)] |
|  |  |  |  |  | *P* < 0.0001 | Pt. (*n* = 95) *vs* Ctrl. (*n* = 21) | (2011) |
|  |  |  |  |  | AUC = 0.86 |  |  |
| I-IV | 98 (PB) | 30 | RT-PCR ELISA | Survivin mRNA | I/II: 25% |  | Cao [[155](#_ENREF_155)] |
|  |  |  |  |  | III/IV: 56.1% | (2011) |
|  |  |  |  |  | I-IV: 45.9% |  |
| I-IV | 93（PB) | 32 | qRT-PCR | piR-651↓ | *P* < 0.001 | Pt. (*n* = 93) *vs* Ctrl. (*n* = 32) | Cui [[49](#_ENREF_49)] |
|  | (42 preo-ope) |  |  |  | AUC = 0.841 |  | (2011) |
|  | (51 post-ope) |  |  | piR-823↓ | *P* < 0.001 |  |  |
|  |  |  |  |  | AUC = 0.822 |  |  |
| II-IV | 35 (PB) | 50 | qRT-PCR | CEA mRNA | 8/35 22.9% | (Pt.) | Dardaei [[156](#_ENREF_156)] |
|  |  |  |  | CK20 mRNA | 13/35 37.1% | (Pt.) | (2011) |
|  |  |  |  | TFF1 mRNA | 11/35 31.4% | (Pt.) |  |
|  |  |  |  | MUC2 mRNA | 22.9% | (Pt.) |  |
|  |  |  |  |  | No detection in controls |  |
| I-IV  | 53 (PB) | 20 | qRT-PCR | miR-21↑ | *P* < 0.0001 | Pt. (*n* = 53) *vs* Ctrl. (*n* = 20) | Zheng [[50](#_ENREF_50)] |
|  |  |  |  |  | AUC = 0.853 |  | (2011) |
| I-IV  | 52 (PB) | 15 | qRT-PCR | miR-200c↑ | *P* = 0.018 | Pt. (*n* = 52) *vs* Ctrl. (*n* = 15) | Valladares-Ayerbes [[51](#_ENREF_51)] |
|  |  |  |  |  | AUC = 0.715 |  | (2012) |
| I-IV | 40 (PB) | 17 | qRT-PCR | miR-421↑ | *P* < 0.01 | Pt. (*n* = 40) *vs* Ctrl. (*n* = 17) | Zhou [[52](#_ENREF_52)] |
|  |  |  |  |  | AUC = 0.773 |  | (2012) |

AUC: Area under the receiver operating characteristic curve; BM: Bone marrow; EGC: Early gastric cancer; EGJ: Esophagogastric junction; GI: Gastrointestinal; MAH: Membrane-array hybridization; PA: Peripheral artery; PB: Peripheral blood; PV: Portal vein; SVC: Superior vena cava; TDB: Tumor-draining blood; N/A: Not available; qRT-PCR: Quantitative real-time polymerase chain reaction; FACS: Fluorescence activated cell sorter; ICC: Intracellular cytokine flow cytometry.

**Table 2 Prognostic value of circulating tumor cells in gastric cancer**

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristic and number of patients** | **Detection method** | **Statistic value** | **Author** |
| 　 | 17 | RT-PCR | CK19 mRNA | OS | *P* = 0.014 | CK19 (+) *vs* (-) | Yeh *et al*[[137](#_ENREF_137)] |
| (non-responsive to chemotherapy) |  |  |  |  |  |  |
| I-IV | 57 | RT-PCR | CEA mRNA | Liver metastasis recurrence | *P* = 0.03 | CEA (+) *vs* (-) | (a) | Miyazono *et al*[[59](#_ENREF_59)] |
| I-IV | 106 | RT-PCR | CEA mRNA | Recurrence/metastasis | *P* = 0.02 | CEA (+) *vs* (-) | (a) | Sumikura *et al*[[141](#_ENREF_141)] |
| I-IV | 41 | RT-PCR | CK20 mRNA | OS | *P* = 0.0363 | CK20 (+) *vs* (-) | (b) | Illert *et al*[[144](#_ENREF_144)] |
| (with curative resection) |  |  |  |  |  |  |  |
| I-III | 46 | RT-PCR | CEA mRNA | Recurrence | *P* ≤ 0.00022 | CEA after sugery (+) *vs* (-) | (a) | Seo *et al*[[145](#_ENREF_145)] |
|  | 　 |  |  | Recurrence | *P* = 0.015 |  | (c) |  |
| I-IV | 52 | RT-PCR | C-Met mRNA | OS | *P* = 0.0178 | C-Met (+) *vs* (-) | (b) | Uen *et al*[[42](#_ENREF_42)] |
|  | 　 |  | MUC1 mRNA | OS | *P* = 0.0352 | MUC1 (+) *vs* (-) | (b) |  |
| I-IV | 42 | RT-PCR | CEA mRNA | Recurrence/metastasis | *P* = 0.032 | CEA (+) *vs* (-) | (c) | Wu *et al*[[43](#_ENREF_43)] |
| I-IV | 64 | MAH | hTERT/CK19/CEA/MUC1 | Recurrence/metastasis | *P* = 0.009 | All marker (+) *vs* the others | (c) | Wu *et al*[[44](#_ENREF_44)] |
|  | 　 |  |  | OS | *P* = 0.0223 |  | (b) |  |
| Metastatic  | 27 | CellSearchSystem | EpCAM | OS | *P* = 0.039 | CTC ≥ 2 *vs* < 2 | (b) | Hiraiwa *et al*[[55](#_ENREF_55)] |
|  | 　 | CK8/18/19 |  |  |  |  |  |
| I-IV | 69 | qRT-PCR | CK19 mRNA | OS | *P* = 0.0347 | CK19 (+) *vs* (-) | (b) | Koga *et al*[[148](#_ENREF_148)] |
| (with curative resection) |  | CK20 mRNA | OS | *P* = 0.049 | CK20 (+) *vs* (-) | (b) |  |
| I-IV | 810 | RT-PCR | MT1-MMP | Recurrence/metastasis | *P* = 0.0018 | MT1-MMP (+) *vs* (-) | (c) | Mimori *et al*[[57](#_ENREF_57)] |
|  | 　 |  |  |  |  |  |  |  |
| I-IV | 55 | RT-PCR ELISA | Survivin mRNA | RFS | *P* = 0.026 | Survivin (+) *vs* (-) | (b) | Yie *et al*[[149](#_ENREF_149)] |
|  | 　 |  |  | *P* = 0.026 |  | (d) |  |
|  I-IV | 70 | qRT-PCR | Survivin mRNA | OS | *P* = 0.036 | Survivin high *vs* low | (b) | Bertazza *et al*[[150](#_ENREF_150)] |
|  | 　 |  |  |  | *P* < 0.001 |  | (d) |  |
| Advanced  | 51  | Cell search system | EpCAM | PFS (2 wk after chemotherapy) | *P* < 0.001 | CTC ≧4 *vs* < 4 | (b) | Matsusaka *et al*[[56](#_ENREF_56)] |
| (2 wk after chemotherapy) |  | CK8/18/19 |  | *P* < 0.001 |  | (d) |  |
|  | 48  |  |  | OS (2 wk after chemotherapy) | *P* < 0.001 |  | (b) |  |
| (4 wk after chemotherapy) |  |  |  | *P* < 0.001 |  | (d) |  |
|  | 　 |  |  | PFS (4 wk after chemotherapy) | *P* < 0.001 |  | (b) |  |
|  | 　 |  |  |  | *P* < 0.001 |  | (d) |  |
|  | 　 |  |  | OS (4 wk after chemotherapy) | *P* < 0.001 |  | (b) |  |
|  | 　 |  |  |  | *P* = 0.004 |  | (d) |  |
| I-IV | 123 | qRT-PCR | CEA mRNA | recurrence | *P* = 0.001 | CEA (+) *vs* (-) | (a) | Qiu *et al*[[152](#_ENREF_152)] |
|  | 　 |  |  | DFS | *P* = 0.001 |  | (b) |  |
|  | 　 |  |  |  | *P* = 0.02 |  | (d) |  |
| I-IV | 30 | qRT-PCR | CK18 mRNA | RFS | *P* < 0.001 | CK18 (+) *vs* (-) | (b) | Saad *et al*[[153](#_ENREF_153)] |
|  (after curative surgery) |  |  |  | *P* = 0.04 |  | (d) |  |
|  | 　 |  |  | OS | *P* = 0.001 |  | (b) |  |
|  | 　 |  |  |  | *P* = 0.06 |  | (d) |  |
| I-IV | 95 | qRT-PCR | B7-H3 mRNA | OS | *P* = 0.02 | B7-H3 high *vs* low | (b) | Arigami *et al*[[154](#_ENREF_154)] |
|  | 　 |  |  |  | *P* = 0.046 |  | (d) |  |
| I-IV | 98 | RT-PCR ELISA | Survivin mRNA | DFS | *P* < 0.001 | Survivin (+) *vs* (-) | (b) | Cao *et al*[[155](#_ENREF_155)] |
|  | 　 |  |  | *P* < 0.001 |  | (d) |  |
| I-IV | 52 | qRT-PCR | miR-200c | OS | *P* = 0.016 | miR-200c high *vs* low | (b) | Valladares-Ayerbes *et al*[[51](#_ENREF_51)] |
|  | 　 |  |  |  | *P* = 0.028 |  | (d) |  |
|  | 　 |  |  | RFS | *P* = 0.044 | miR-200c high *vs* low | (b) |  |
|  | 　 |  |  |  | *P* = 0.028 |  | (d) |  |

a: *χ*2 test/Fisher's exact test; b: Kaplan-Meier survival curves, Log-rank test/Breslow-Wilcoxon test; c: Logistic regression model (multivariate); d: Multivariate Cox proportional hazard regression model. DFS: Disease-free survival; MAH: Membrane-array hybridization; OS: Overall survival; PFS: Progression-free surviva; qRT-PCR: Quantitative real-time polymerase chain reaction; RFS: Relapse-free survival; N/A: Not available.

**Table 3 Circulating cell-free DNA in gastric cancer**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Characteristic and number of patients** | **Controls (*n*)** | **Plasma/serum** | **Detection method** | **Detection rate/statistic value** | **Author** |
| Unresectable  | 198 | 78 (peptic ulcer) | Serum | Immuno-PCR | MG7-Ag | 82.8% | (GC) |  | Ren *et al*[[157](#_ENREF_157)] |
|  |  | 118 (chronic gastritis) |  | Semi quantitativePCR | 7.7% | (peptic ulcer) |  |  |
|  |  | 236 (healthy donors) |  |  |  | 5.9% | (chronic gastritis) |  |  |
|  |  |  |  |  |  | 0.8% | (healthy donors) |  |  |
|  |  |  |  |  |  | *P* < 0.01 | Correlation with metastasis | (a) |  |
| N/A | 51 | 30 (gastritis) | Serum | qPCR | EBV DNA | 100% | (Pt. with EBER (+)in primary tumor) |  | Lo *et al*[[158](#_ENREF_158)] |
|  |  | 197 (helthy controls) |  |  |  | 92.9% | (Pt. with EBER (+)in filtrating lymphocytes) |  |  |
|  |  |  |  |  |  | 0% | (Pt. with EBER (-)in primary tumor) |  |  |
|  |  |  |  |  |  | 23.3% | (gastritis) |  |  |
|  |  |  |  |  |  | 3.6% | (Ctrl.) |  |  |
| I-IV  | 54 | 30 | Serum | MSP | DAP-kinase | 48.1% |  |  | Lee *et al*[[85](#_ENREF_85)] |
|  |  |  |  |  | E-cadherin | 57.4% |  |  |  |
|  |  |  |  |  | GSTP1 | 14.8% |  |  |  |
|  |  |  |  |  | p15 | 55.6% |  |  |  |
|  |  |  |  |  | p16 | 51.9% |  |  |  |
|  |  |  |  |  |  | No detection in controls |  |  |
| I-IV  | 60 | 16 | Serum | MSP | p16 | 26.1% | With p16 methylationin primariy tumor |  | Kanyama *et al*[[159](#_ENREF_159)] |
|  |  |  |  |  |  | 0% | Without p16 methylationin primariy tumor |  |  |
|  |  |  |  |  |  | 0% | (Ctrl.) |  |  |
| I-IV  | 109 | 10 | Serum | MSP | p16 | 18.3% |  |  | Ichikawa *et al*[[160](#_ENREF_160)] |
|  |  |  |  |  | E-cadherin | 23.9% |  |  |  |
|  |  |  |  |  | p16+E-cadherin | 36.7% |  |  |  |
|  |  |  |  |  |  | No detection in controls |  |  |
|  |  |  |  |  | E-cadherin | 22.0% |  |  |  |
|  |  |  |  |  | RARb | 14.6% |  |  |  |
|  |  |  |  | p16+E-cadherin+RARb | 24.4% |  |  |  |
|  |  |  |  |  |  | No detection in controls |  |  |
| I-IV  | 63 | 10 | Serum | MSP | p16 | 27.0% |  |  | Koike *et al*[[161](#_ENREF_161)] |
|  |  |  |  |  | E-cadherin | 23.8% |  |  |  |
|  |  |  |  |  | RARb | 17.5% |  |  |  |
|  |  |  |  | p16+E-cadherin+RARb | 50.8% |  |  |  |
|  |  |  |  |  |  | No detection in controls |  |  |
| I-IV  | 60 | 22 | Serum | qMSP | APC | 16.7% |  |  | Leung *et al*[[162](#_ENREF_162)] |
|  |  |  |  |  | E-cadherin | 13.3% |  |  |  |
|  |  |  |  |  | hMLH1 | 41.7%% |  |  |  |
|  |  |  |  |  | TIMP3 | 16.7% |  |  |  |
|  |  |  |  | Four markers combined | 55% |  |  |  |
|  |  |  |  |  |  | 13.6% | (Ctrl.) |  |  |
|  |  |  |  |  | APC+E-cadherin | OS: *P* = 0.006 | Methylation (+) *vs* (-) | (b) |  |
| I-IV  | 109 | 10 | Serum | MSP | RARb | 23.8% |  |  | Ikoma *et al*[[163](#_ENREF_163)] |
|  |  |  |  | p16+E-cadherin+RARb | 47.7% |  |  |  |
| I-IV  | 53 | 21 | Plasma | qPCR | β-actin (102bp) | *P* = 0.03 | Pt.(*n* = 53) *vs* Ctrl. (*n* = 21) | (c) | Sai *et al*[[83](#_ENREF_83)] |
|  |  |  |  |  | β-actin (253bp) | *P* < 0.0001 |  | (c) |  |
|  |  |  |  |  |  | AUC = 0.75 |  |  |  |
|  |  |  |  | DNA integrity (253 bp/102 bp) | *P* = 0.07 |  | (c) |  |
| N/A | 4 | 10 | Serum | MSP | RUNX3 | 100% |  |  | Tan *et al*[[164](#_ENREF_164)] |
|  |  |  |  |  | p16 | 50% |  |  |  |
|  |  |  |  |  | RASSF1A | 25% |  |  |  |
|  |  |  |  |  | CDH1 | 25% |  |  |  |
|  |  |  |  |  |  | No detection in controls |  |  |
| I-IV | 52 | 20 | Serum | MSP | p16 | 9.6% |  |  | Tani *et al*[[147](#_ENREF_147)] |
|  | (40 pre-ope) |  |  |  | E-cadherin | 9.6% |  |  |  |
|  | (12 post-ope) |  |  |  | RARb | 3.8% |  |  |  |
|  |  |  |  | p16+E-cadherin+RARb | 23.1% |  |  |  |
| I-IV  | 52 | 50 | Serum | MSP | p16 | 26.9% | (all Pt.) |  | Abbaszadegan *et al*[[165](#_ENREF_165)] |
|  |  |  |  |  |  | 60.9% | (Pt. with p16 methylationin primary tumor) |  |  |
|  |  |  |  |  |  | 0% | (Ctrl.) |  |  |
| I-IV  | 20 | 22 | Plasma | Fluorescence-based assay | DNA concentration↑ | *P* < 0.005 | Pt.(*n* = 20) *vs* Ctrl. (*n* = 22) | (d) | Kolesnikova *et al*[[166](#_ENREF_166)] |
|  |  |  |  | MSP | MGMT | 70% | (Pt.) |  |  |
|  |  |  |  |  |  | 36.4% | (Ctrl.) |  |  |
|  |  |  |  |  | p15 | 50% | (Pt.) |  |  |
|  |  |  |  |  |  | 18.2% | (Ctrl.) |  |  |
|  |  |  |  |  | hMLH1 | 25% | (Pt.) |  |  |
|  |  |  |  |  |  | 9.1% | (Ctrl.) |  |  |
| I-IV  | 47 | 30 (benign gastric disease) | Serum | MSP | RASSF1A | 24.0% | (Pt.) |  | Wang *et al*[[167](#_ENREF_167)] |
|  |  | 30 (healthy controls) |  |  |  | 3.3% | (benign gastric disease) |  |  |
|  |  |  |  |  |  | 0% | (healthy controls) |  |  |
| I-IV  | 20 | 21 | Serum | MSP | HSulf-1 | 55% | (Pt.) |  | Chen *et al*[[168](#_ENREF_168)] |
|  |  |  |  |  |  | 19.0% | (Ctrl.) |  |  |
| I-IV  | 57 | 79 | Plasma | qPCR | MYC/GAPDH↑ | *P* < 0.001 | Pt.(*n* = 57) *vs* Ctrl. (*n* = 79) |  | Park *et al*[[91](#_ENREF_91)] |
|  |  |  |  |  |  | AUC = 0.841 |  |  |  |
| I-IV  | 65 | 50 | Serum | qMSP | RUNX3 | 29.2% | (Pt.) |  | Sakakura *et al*[[169](#_ENREF_169)] |
|  |  |  |  |  |  | 10% | (Ctrl.) |  |  |
|  |  |  |  |  |  | AUC = 0.8651 | Pt.(*n* = 65) *vs* Ctrl. (*n* = 50) |  |  |
| I-IV  | 65 | 40 (benign gastric disease) | Serum | MSP | DLEC1 | 33.8% | (Pt.) |  | Zhang *et al*[[170](#_ENREF_170)] |
|  |  | 20 (healthy controls) |  |  |  | 5% | (benign gastric disease) |  |  |
|  |  |  |  |  |  | 0% | (healthy controls) |  |  |
| I-IV  | 73 | 20 | Serum | qMSP | TFPI2 | 9.6% | (Pt.) |  | Hibi *et al*[[171](#_ENREF_171)] |
|  |  |  |  |  |  | 0% | (Ctrl.) |  |  |
|  |  |  |  |  |  | *P* = 0.004 | Correlation with LN meta. | (a) |  |
|  |  |  |  |  |  | *P* = 0.0115 | Correlation with distant meta. | (a) |  |
| I-IV  | 65 | 80 | Plasma | qMSP | SLC19A3 | *P* < 0.0001 | Pt.(*n* = 45) *vs* Ctrl. (*n* = 60)(Validation 1) |  | Ng *et al*[[172](#_ENREF_172)] |
|  |  |  |  |  |  | AUC = 0.82 | Pt.(*n* = 20) *vs* Ctrl. (*n* = 20)(Validation 2) |  |  |
| I-IV  | 46 | 30 (healthy controls) | Serum | Methylation CpGisland microarray | BX141696 | 56.5% |  |  | Zheng *et al*[[86](#_ENREF_86)] |
|  |  | 46 (benign gastric disease) |  | MSP | WT1 | 50% |  |  |  |
|  |  |  |  | CYP26B1 | 73.9% |  |  |  |
|  |  |  |  |  | KCNA4 | 67.4% |  |  |  |
| I-IV  | 58 | 30 (healthy controls) | Serum | MeDIP | CHRM2 | 31.0% |  |  | Chen *et al*[[87](#_ENREF_87)] |
|  |  | 46 (gastric precancerous lesions) |  | Methylation CpGisland microarray | FAM5C | 31.0% |  |  |  |
|  |  |  | MSP |  | *P* < 0.001 | Pre- *vs* post-operation |  |  |
|  |  |  |  |  | MYLK | 70.7% |  |  |  |
|  |  |  |  |  |  | *P* < 0.001 | Pre- *vs* post-operation |  |  |
|  |  |  |  |  | FAM5C+MYLK | 77.6% | (GC Pt.) |  |  |
|  |  |  |  |  |  | 10% | (healthy controls) |  |  |
|  |  |  |  |  |  | 30.4% | (gastric precancerous lesions) |  |  |
| I-IV  | 59 | 54 | Plasma | qPCR | ALU↑ | *P* < 0.001 | Pt.(*n* = 59) *vs* Ctrl. (*n* = 54) | (c) | Park *et al*[[84](#_ENREF_84)] |
|  |  |  |  |  |  | AUC = 0.784 |  |  |  |
| N/A | 25 | 9 | Plasma | MSP | ATP4B | 64% | (Pt.) |  | Raja *et al*[[173](#_ENREF_173)] |
|  |  |  |  |  |  | 0% | (Ctrl.) |  |  |
| I-IV  | 71 | 21 | Serum | qMSP | Vimentin | *P* = 0.018 | Pt.(*n* = 73) *vs* Ctrl. (*n* = 21) | (c) | Shirahata *et al*[[174](#_ENREF_174)] |
| Operable | 73 | 20 | Serum | MSP | SOX17 | 58.9% | (Pt.) |  | Balgkouranidou  *et al*[[175](#_ENREF_175)] |
|  |  |  |  |  |  | 0% | (Ctrl.) |  |  |
|  |  |  |  |  |  | OS: *P* = 0.049 | methylation (+) *vs* (-) | (b) |  |
| I-IV  | 73 |  | Plasma | qPCR | HER2 | 64.4% | Pt. with 2+/3+ score in HER2 IHC assay |  | Lee *et al*[[92](#_ENREF_92)] |
| Pt. with 2+/3+ score in HER2 IHC assay |  |  |  |  |  |  |  |  |
| I-IV | 202 | 88 | Serum | qMSP | XAF1 | 69.8% | (Pt.) |  | Ling *et al*[[88](#_ENREF_88)] |
|  |  |  |  |  |  | 0% | (Ctrl.) |  |  |
|  |  |  |  |  |  | AUC = 0.909 | Pt. (*n* = 202) *vs* Ctrl.(*n* = 88) |  |  |
|  |  |  |  |  |  | DFS: *P* < 0.0001 | Methylation (+) *vs* (-) | (b) |  |

a: *χ*2 test/Fisher's exact test; b: Kaplan-Meier survival curves, Log-rank test/Breslow-Wilcoxon test; c: Unpaired *t*-test/Mann-Whitney *U*-test; d: Unknown statistic method. AUC: Area under the receiver operating characteristic curve; LN: Lymph node; MeDIP: Methylated DNA immunoprecipitation; MSP: Methylation specific-PCR; qMSP: Quantitative methylation specific-PCR.

qRT-PCR: Quantitative real-time polymerase chain reaction; N/A: Not available.

**Table 4 Circulating cell-free mRNA in gastric cancer**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Characteristic and number of patients** | **Controls (*n*)** | **Plasma/serum** | **Detection method** | **Detection rate/statistic value** | **Author****(Year)** |
| I-IV  | 52 | 20 | Plasma | qRT-PCR | hTERT | 7.5% | (preoperative) |  | Tani *et al*[[147](#_ENREF_147)] |
|  | (40 preoperative) |  |  |  | MUC1 | 10% |  |  |  |
|  | (12 postoperative) |  |  |  | hTERT+MUC1 | 15% |  |  |  |
|  |  |  |  |  | hTERT | 16.7% | (postoperative) |  |  |
|  |  |  |  |  | MUC1 | 8.3% |  |  |  |
|  |  |  |  |  | hTERT+MUC1 | 16.7% |  |  |  |
|  |  |  |  |  |  | No detection in controls |  |  |
| I-IV  | 89 | 42 | Plasma | qRT-PCR | CXCR4↑ | 41.6% | [before surgery (*n* = 89)) | Xu *et al*[[176](#_ENREF_176)] |
| (paired, before andafter surgery (*n* = 69)) |  |  |  |  | 23.2% | [after surgery (*n* = 69)] |  |
|  |  |  |  | 21.4% | (Ctrl. (*n* = 42)) |  |  |
|  |  |  |  |  |  | *P* < 0.05 | Before surgery (*n* = 89) *vs* Ctrl. (*n* = 42) | (a) |  |
|  |  |  |  |  | Bmi-1↑ | 57.3% | [before surgery (*n* = 89)] |  |
|  |  |  |  |  |  | 43.5% | [after surgery (*n* = 69)] |  |
|  |  |  |  |  |  | 28.6% | [Ctrl. (*n* = 42)] |  |  |
|  |  |  |  |  |  | *P* < 0.05 | Before surgery (*n* = 89) *vs* Ctrl. (*n* = 42) | (a) |  |
|  |  |  |  |  |  | *P* < 0.05 | Before (*n* = 89) *vs* after (*n* = 69) surgery | (a) |  |
| I-IV  | 118 | 40 (gastritis) | Plasma | qRT-PCR | hTERT mRNA↑ | *P* < 0.05 | GC (*n* = 118) *vs* gastritis (*n* = 40) | (a) | Kang *et al*[[123](#_ENREF_123)] |
|  |  | 58 (healthy controls) |  |  |  | *P* < 0.05 | GC (*n* = 118) *vs* Ctrl. (*n* = 58) | (a) |  |
|  |  |  |  |  |  | AUC = 0.891 | GC (*n* = 118) *vs* Ctrl. (*n* = 58) |  |
|  |  |  |  |  |  | DFS: *P* < 0.001 |  | (b) |  |
|  |  |  |  |  |  | DFS: *P* = 0.001 |  | (c) |  |
|  |  |  |  |  |  | OS: *P* < 0.001 |  | (b) |  |
|  |  |  |  |  |  | OS: *P* < 0.001 |  | (c) |  |

a: Mann-Whitney U-test; b: Kaplan-Meier survival curves, Log-rank test/Breslow-Wilcoxon test; c: Multivariate Cox proportional hazard regression model. AUC: Area under the receiver operating characteristic curve; DFS: Disease-free survival; OS: Overall survival.

**Table 5 Circulating cell-free microRNA/long non-coding RNA in gastric cancer**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Characteristic and number of patients** | **Controls (*n*)** | **Plasma/serum** | **Detection method** | **Detection rate/statistic value** | **Author** |
| **microRNA** |  |  |  |  |  |  |  |  |  |
| I-IV  | 69 | 30 | Plasma | qRT-PCR | miR-17-5p↑ | *P* = 0.05 |  | Pt. (*n* = 69) *vs* Ctrl (*n* = 30) | (a) | Tsujiura *et al*[[124](#_ENREF_124)] |
|  | 　 |  |  |  | miR-21↑ | *P* = 0.006 |  | Pt. (*n* = 69) *vs* Ctrl (*n* = 30) | (a) |  |
|  | 　 |  |  |  |  | *P* = 0.013 |  | paired (*n* = 10), pre-op > post-op | (b) |  |
|  | 　 |  |  |  | miR-106a↑ | *P* = 0.008 |  | Pt. (*n* = 69) *vs* Ctrl (*n* = 30) | (a) |  |
|  | 　 |  |  |  | miR-106b↑ | *P* < 0.001 | AUC = 0.721 | Pt. (*n* = 69) *vs* Ctrl (*n* = 30) | (a) |  |
|  | 　 |  |  |  |  | *P* = 0.022 |  | paired (*n* = 10), pre-op > post-op | (b) |  |
|  | 　 |  |  |  | let-7a↓ | *P* = 0.002 |  | Pt. (*n* = 69) *vs* Ctrl (*n* = 30) | (a) |  |
|  | 　 |  |  |  | miR-106a/let-7a↑ |  | AUC = 0.879 |  |  |  |
| I-IV  | 164 | 127 | Serum | Solexa sequencing | miR-1↑ | *P* < 0.01 | Pt. (*n* = 164) *vs* Ctrl (*n* = 127) | (a) | Liu  *et al*[[177](#_ENREF_177)] |
|  | 　 |  |  | qRT-PCR | miR-20a↑ | *P* < 0.01 |  |  | (a) |  |
|  | 　 |  |  |  | miR-27a↑ | *P* < 0.01 |  |  | (a) |  |
|  | 　 |  |  |  | miR-34a↑ | *P* < 0.01 |  |  | (a) |  |
|  | 　 |  |  |  | miR-423-5p↑ | *P* < 0.01 |  |  | (a) |  |
|  | 　 |  |  |  | Five-serum miRNA signature↑ | AUC = 0.879 | Pt. (*n* = 22) *vs* Ctrl (*n* = 22) (test study) |  |
|  | 　 |  |  |  |  | AUC = 0.831 | Pt. (*n* = 142) *vs* Ctrl (*n* = 105) (validation study) |  |
|  | 　 |  |  |  |  |  |  |  |  |  |
| I-IV  | 56 | 30 | Plasma | Microarray | miR-451↑ | *P* < 0.01 | AUC = 0.96 | Pt. (*n* = 56) *vs* Ctrl (*n* = 30) | (a) | Konishi  *et al*[[125](#_ENREF_125)] |
|  | 　 |  |  | qRT-PCR |  | *P* < 0.01 |  | paired (*n* = 29), pre-op > post-op | (b) |  |
|  | 　 |  |  |  | miR-486↑ | *P* < 0.01 | AUC = 0.92 | Pt. (*n* = 56) *vs* Ctrl (*n* = 30) | (a) |  |
|  | 　 |  |  |  |  | *P* < 0.01 |  | paired (*n* = 29), pre-op > post-op | (b) |  |
|  | 　 |  |  |  |  |  |  |  |  |  |
| I-IV  | 40 | 41 | Serum | Microarray | miR-187\*↑ | *P* = 0.0016 | AUC = 0.704 | Pt. (*n* = 40) *vs* Ctrl (*n* = 41) | (a) | Liu  *et al*[[178](#_ENREF_178)] |
|  | 　 |  |  | qRT-PCR | miR-371-5p↑ | *P* = 0.0009 | AUC = 0.715 |  | (a) |  |
|  | 　 |  |  |  | miR-378↑ | *P* < 0.0001 | AUC = 0.861 |  | (a) |  |
|  | 　 |  |  |  |  |  |  |  |  |  |
| N/A | 82 | 82 | Serum | Microarray | miR-221↑ | AUC = 0.74 | Pt. (*n* = 68) *vs* Ctrl (*n* = 68) (second validation study) | Song  *et al*[[179](#_ENREF_179)] |
|  | 　 |  |  | qRT-PCR | miR-376c↑ | AUC = 0.71 |  |  |  |  |
|  | 　 |  |  |  | miR-744↑ | AUC = 0.71 |  |  |  |  |
| N/A | 20 |  | Serum | qRT-PCR | miR-196a | *P* = 0.012 | Pre-op (*n* = 20) > post-op (*n* = 20) | (a) | Tsai  *et al*[[180](#_ENREF_180)] |
| (pre-op,post-opand recurrent)　 |  |  |  |  | *P* = 0.002 | Post-op (*n* = 20) < at recurrent (*n* = 20) | (a) |  |
|  |  |  |  |  |  |  |  |  |
| I-IV  | 30 | 39 | Serum | qRT-PCR | miR-21↑ | *P* < 0.001 | AUC = 0.81 | Pt. (*n* = 30) *vs* Ctrl (*n* = 39) | (a) | Wang  *et al*[[181](#_ENREF_181)] |
| I-IV  | 87 |  | Plasma | qRT-PCR | miR-17-5p↑ | *P* < 0.001 |  | Pre-op (*n* = 65) > post-op (*n* = 16) | (a) | Wang  *et al*[[182](#_ENREF_182)] |
|  | (65 pre-op) |  |  |  |  | *P* = 0.003 |  | Post-op (*n* = 16) < recurrent (*n* = 6) | (a) |  |
|  | (16 post-op) |  |  |  |  | OS: *P* = 0.0003 | miR-17-5p high *vs* low | Pre-op (*n* = 65) | (c) |  |
|  | (6 recurrent) |  |  |  | miR-20a↑ | *P* = 0.006 |  | Pre-op (*n* = 65) > post-op (*n* = 16) | (a) |  |
|  | 　 |  |  |  |  | OS: *P* = 0.0003 | miR-20a high *vs* low | Pre-op (*n* = 65) | (c) |  |
|  | 　 |  |  |  |  | OS: *P* = 0.013 | miR-20a high *vs* low | pre-op (*n* = 65) | (d) |  |
| I-IV  | 20 | 20 | Serum | miRNA microarray | miR-375↓ | *P* < 0.001 | AUC = 0.835 | Pt. (*n* = 20) *vs* Ctrl (*n* = 20) | (a) | Zhang  *et al*[[183](#_ENREF_183)] |
|  | 　 |  |  | qRT-PCR |  |  |  |  |  |  |
|  | 20 | 190 | Plasma | miRNA microarray | miR-195-5p↓ | *P* < 0.05 | Fold changes= 13.3 | Pt. (*n* = 20) *vs* Ctrl (*n* = 130) | (a) | Gorur  *et al*[[184](#_ENREF_184)] |
| I-III | 79 |  |  |  | miR-21↑ | *P* < 0.001 | Correlation with pN stage | (e) | Kim  *et al*[[185](#_ENREF_185)] |
| (25 without LN meta) |  |  |  | miR-146a↑ | *P* = 0.001 | Correlation with pN stage | (e) |  |
| (54 with LN meta) |  |  |  | miR-148a↑ | *P* < 0.001 | Correlation with pN stage | (e) |  |
| I-IV  | 69 |  | Plasma | qRT-PCR | miR-21↑ | CSS: *P* = 0.0451 | miR-21 high *vs* low | (c) | Komatsu  *et al*[[186](#_ENREF_186)] |
|  | 　 |  |  |  |  | CSS: *P* = 0.0133 |  |  | (d) |  |
| I-II | 80 | 70 | Plasma | qRT-PCR | miRNA-199a-3p↑ | *P* < 0.001 | AUC = 0.818 | Pt. (*n* = 80) *vs* Ctrl. (*n* = 70) | (a) | Li  *et al*[[187](#_ENREF_187)] |
|  | 　 | (healthy controls) |  |  |  | *P* = 0.004 | Pt. (*n* = 80) *vs* pancreous disease (*n* = 20) | (a) |  |
|  | 　 | 20 |  |  |  | *P* = 0.012 | Pre-op > post-op (*n* = 30) | (b) |  |
|  |  | (precancerous disease) |  |  |  |  |  |  |  |  |
| **Long non-coding RNA** |  |  |  |  |  |  |  |  |  |
| I-IV  | 43 | 33 | Plasma | qRT-PCR | H19 | *P* = 0.029 |  | Pt. (*n* = 43) *vs* Ctrl. (*n* = 33) | (a) | Arita  *et al*[[128](#_ENREF_128)] |
|  | 　 |  |  |  | HOTAIR | *P* = 0.096 |  |  | (a) |  |
|  | 　 |  |  |  | MALAT1 | *P* = 0.14 |  |  | (a) |  |

a: Unpaired *t*-test/Mann-Whitney *U*-test; b: Wilcoxon test; c: Kaplan-Meier survival curves, Log-rank test; d: Logistic regression model (multivariate); e: Kruskal-Wallis test.

AUC: Area under the receiver operating characteristic curve; CSS: Cause-specific survival; LN: Lymph node; N/A: Not available; qRT-PCR: Quantitative real-time polymerase chain reaction.